Scientific Schedule & Program

Tuesday, 24. May 2016

Registration
10:00 - 19:00
Level 3

Registration

Trainee Session
13:00 - 14:30
Rondelet

Trainee Session 1: Collaboration Between Emerging Countries and Established Teams
Co-Chair: Assad Haffar (Canada)
Co-Chair: Saliou Diop (Senegal)

13:00
How to Organize Trainings in Foreign Countries? Contacts, Grants and Management
Speaker: Angelika Batorova (Slovakia)

13:45
Use of New Technologies for Learning, Collaboration and Exchanges: E-learning, Telemedicine
Speaker: Damien Dietrich (Switzerland)

Trainee Session
15:00 - 16:30
Rondelet

Trainee Session 2: How to Build a Research Project
Co-Chair: Ophila Salomon (Israel)
Co-Chair: Nadia Rosencher (France)

15:00
Methodological Aspects: From Observational Studies to Randomized Trials
Speaker: Marc Blondon (Switzerland)

15:45
How to Become a Principal Investigator
Speaker: Philip de Groot (Netherlands)

Trainee Session
17:00 - 18:30
Antigone 2

Trainee Networking Event
Chair: Jean-François Schved (France)
Scientific Schedule & Program

Wednesday, 25. May 2016

Registration
07:00 - 18:30  Level 3

Master Class Session
07:30 - 08:15  Rondelet

Master Class
Which Bleeding Scores for Either Children and/or Adults?
Speaker: Alberto Tosetto (Italy)

Master Class Session
07:30 - 08:15  Barthez

Master Class
Long Acting Factors in Hemophilia: How to Use Them?
Speaker: Claude Negrier (France)

Master Class Session
07:30 - 08:15  Sully 1

Master Class
Identifying Risk Factors Using Gwas: Useful?
Speaker: Pierre Morange (France)

Master Class Session
07:30 - 08:15  Sully 2

Master Class
Tyrosine Phosphorylation and Platelet Activation
Speaker: Yotis Senis (United Kingdom)
**Scientific Schedule & Program**

**Education Session**
08:30 - 10:00

**Education Session 1 – New Treatments in Hemostasis: New Approaches**
Co-Chair: Mark Crowther (Canada)
Co-Chair: Jean-Pierre Laroche (France)

- **Antiplatelet Therapy**
  Speaker: Marco Cattaneo (Italy)  
  08:30

- **Targeting Factor XI or Factor XII**
  Speaker: Nigel Key (United States)  
  09:00

- **New Insight on Fibrinolysis**
  Speaker: Robert Medcalf (Australia)  
  09:30

**Education Session**
08:30 - 10:00

**Education Session 2 – Endothelial Cells and its Disorders: Vascular Biology**
Co-Chair: Jose Lopez (United States)
Co-Chair: Françoise Dignat-George (France)

- **Cardiovascular Aging: The Role of Non-Coding RNA**
  Speaker: Reinier Boon (Germany)  
  08:30

- **Vascular Biology, Brain Vessels and Diseases**
  Speaker: Anne Eichmann (United States)  
  09:00

- **Endothelial Cell Pathophysiology in Pulmonary Hypertension**
  Speaker: David Smadja (France)  
  09:30

**Exhibition**
09:45 - 17:00

**Exhibition**

**Education Session**
10:30 - 12:00

**Education Session 1 – New Treatments in Hemostasis: Controversies About New Oral Anticoagulant Treatments**
Co-Chair: Walter Ageno (Italy)
Co-Chair: Marc Samama (France)

- **NOACs or Vitamin K Antagonist: Balancing the Choices**
  Speaker: Sam Schulman (Canada)  
  10:30

- **How to Reverse NOAC Effects?**
  Speaker: Andreas Greinacher (Germany)  
  11:15
Scientific Schedule & Program

Education Session
10:30 - 12:00  

**Education Session 2 – Endothelial Cells and its Disorders: Focus on Endothelium**

Co-Chair: Pierre Mangin (France)  
Co-Chair: Ruben Bierings (Netherlands)

- **The Role of Platelets in the Development of the Lymphatics and Cerebrovasculature, and in Vascular Integrity**  
  Speaker: Stephen Watson (United Kingdom)
  
- **Endothelial Cells, Platelets and Neutrophils: Key Players in Thrombus Formation**  
  Speaker: Christophe Dubois (France)
  
- **Differentiation of Pluripotent Stem Cells in Endothelial Cells: Translation to Renal Diseases**  
  Speaker: Mervin Yoder (United States)

Corporate Symposium
12:45 - 14:00  

**Corporate Symposium-CS01**

For additional information, please [click here](#)

- **Bayer (Hemophilia): Bayer’s Commitment to Advancing Hemophilia Care: KOVALTRY® (Recombinant Factor VIII [Octocog Alfa]) in the Spotlight**  
  
- **Welcome and Introduction**  
  Speaker: Claude Negrier (France)
  
- **Protein Structure and Function: The Role of Glycosylation and Sialylation**  
  Speaker: Stephen Garger (United States)
  
- **Characterizing the Advances in Manufacturing and Clinical Outcomes With KOVALTRY®**  
  Speaker: Gili Kenet (Israel)
  
- **Improving Outcomes in Bleeding Disorders: Bayer’s Commitment to Research**  
  Speaker: Claude Negrier (France)
  
- **Questions and Answers**

Corporate Symposium-CS02

For additional information, please [click here](#)

- **Sobi: Protection Through Technology and Clinical Application**
Scientists Schedule & Program

**Introduction to Fc Fusion Characteristics**  
Speaker: Roseline d’Oiron (France)  
12:45

**Reliability of Laboratory Measurements**  
Speaker: Steve Kitchen (United Kingdom)  
12:55

**Clinical Trial Programme: “A-LONG” Experience**  
Speaker: Robert Klamroth (Germany)  
13:10

**How to Use Elocta®**  
Speaker: Cedric Hermans (Belgium)  
13:30

**Questions & Answers and Closing Remarks**  
13:50

---

**Corporate Symposium**  
12:45 - 14:00  
Antigone 1

**Corporate Symposium-CS03**

For additional information, please [click here](#)

**Boehringer Ingelheim: Advancing Anticoagulation: Impact of Reversal Agents**

**A New Era in Anticoagulation: Where Does the Evidence Lead us in 2016?**  
Speaker: Elaine Hylek (United States)  
12:45

**NOAC Reversal Agents: New Developments and Latest Data**  
Speaker: Jeffrey I. Weitz (Canada)  
13:05

**Anticoagulation Reversal in Practice: Case-Based Discussion**  
Speaker: Steve Austin (United Kingdom)  
Speaker: Chris Ward (Australia)  
13:25

**Q&A**  
Speaker: Jeffrey I. Weitz (Canada)  
13:50

---

**SSC Session**  
14:15 - 16:15  
Pasteur

**Von Willebrand Factor, Part I**

**Introductory Remarks**  
Speaker: Jorge Di Paola (United States)  
14:15

**Featured Abstract Presentation: Blood Outgrowth Endothelial Cells From Type 3 Von Willebrand Disease Patients Display Abnormal Angiogenesis**  
Speaker: Soundarya Nivedita Selvam (Canada)  
14:25

**GP1ba/VWF Relationship: Scientific, Laboratory and Clinical Relevance, Moderators: Sandra Haberichter, United States and Koichi Kokame, Japan**

Moderator: Sandra Haberichter (United States)  
Moderator: Koichi Kokame (Japan)  
14:30
62nd Annual SSC Meeting of the ISTH,
Montpellier, France,
May 25-28, 2016

Scientific Schedule & Program

VWF-Platelet Relationship, Implications for VWD
Speaker: Peter Lenting (France)  14:40

Role of Free Hemoglobin on VWF-Mediated Platelet Adhesion
Speaker: Miguel Cruz (United States)  15:00

Adhesive Force Between VWF and GPIba
Speaker: Shinya Goto (Japan)  15:20

GP1b- Based Assays
Speaker: Sandra Haberichter (United States)  15:30

VWF Activity Assays
Speaker: Emmanuel Favaloro (Australia)  15:45

Standardization of GP1b- Based Assays
Speaker: Anthony Hubbard (United Kingdom)  15:55

Discussion
Speaker: Dorothy Adcock-Funk (United States)  16:05

SSC Session
14:15 - 16:15  Einstein

Lupus Anticoagulant/Antiphospholipid Antibodies

Opening
Speaker: Bas de Laat (Netherlands)  14:15

Featured Abstract Presentation: Inverted Erythrocyte Membranes as a Novel Model for Studying the Antiphospholipid Syndrome
Speaker: Saartje Bloemen (Netherlands)  14:20

IgG and IgM Antiphospholipid Antibodies Present in the Classification Criteria of the Antiphospholipid Syndrome and Their Association With Thrombosis: A Critical Review of the Literature
Speaker: Katrien Devreese (Belgium)  14:35

ELISA Validation Within the APS Action Consortium
Speaker: Maria Laura Bertolaccini (United Kingdom)  14:50

Multicenter Study on Solid Phase Assays
Speaker: Hilde Kelchtermans (Netherlands)  15:05

Controversies in dRVVT Testing
Speaker: Thomas Exner (Australia)
Speaker: Gary Moore (United Kingdom)  15:20

What Is LAC and How to Use It?
Speaker: Rolf Urbanus (Netherlands)  15:35

LA Algorithms and Normalization
Speaker: Jovan Antovic (Sweden)  15:50
Investigation of Cut-Off Values for the Detection of Lupus Anticoagulants - Results of an International Multicenter Multiplatform Study
Speaker: Armando Tripodi (Italy)

SSC Session
14:15 - 16:15
Antigone 1

Working Group on Perioperative Thrombosis and Hemostasis

Featured Abstract Presentation: Thromboelastography and Thrombin Generation Test Follow-Up in Patients Developing Sepsis or Systemic Inflammatory Response Syndrome
Speaker: Isabelle Gouin-Thibault (France)

Perioperative Management of Antithrombotic Agents, Moderators: James Douketis, Canada and Jerrold Levy, United States
Moderator: James Douketis (Canada)
Moderator: Jerrold Levy (United States)

Management of Patients on Antiplatelet Therapy for Urgent and Elective Surgery
Speaker: Pierre Albaladejo (France)

Platelet Transfusion and Other Rescue Solutions in DAPT Patients?
Speaker: Thomas Thiele (Germany)

Management of Anticoagulated Patients (VKAs and DOACs) Who Need Elective Surgery
Speaker: Alex Spyropoulos (United States)

Management of Patients on DOACs Who Need Urgent Surgery
Speaker: Jerrold Levy (United States)

SSC Session
14:15 - 16:15
Antigone 3

Pediatric and Neonatal Thrombosis and Hemostasis

Moderators: Anthony Chan, Canada and Leonardo Brandao, Canada
Speaker: Anthony Chan (Canada)

Introduction/Report
Speaker: Anthony Chan (Canada)

Featured Abstract Presentation: Characterization of Laboratory Coagulation Parameters and Risk Factors for Intraventricular Hemorrhage (IVH) in Extremely Premature Neonates
Speaker: Jonathan Roberts (United States)

Anticoagulation for Shunt and Stent
Speaker: Christoph Male (Austria)

Monitoring of Anticoagulation Therapy: Alternative
Speaker: Meera Chitlur (United States)
**Scientific Schedule & Program**

**Congenital Antithrombin Deficiency Registry**  
Speaker: Riten Kumar (United States)  
15:15

**Psychosocial and Adherence for Patient on Chronic Anticoagulation Therapy**  
Speaker: Fiona Newall (Australia)  
15:25

**VTE Working Group: Arterial Thrombosis**  
Speaker: Mattia Rizzi (Switzerland)  
15:45

**VTE Working Group: VTE Prophylaxis**  
Speaker: Brian Branchford (United States)  
15:55

**VTE Working Group: Pulmonary Embolism**  
Speaker: Heleen Van Ommen (Netherlands)  
16:05

**SSC Session**  
14:15 - 16:15  
Rondelet

**Fibrinolysis**

**Hyperfibrinolysis in Trauma Induced Coagulopathy (TIC) - What’s Different and How Do We Manage It?**

Opening Remarks & Announcements  
Speaker: Nicola Mutch (United Kingdom)  
14:15

Featured Abstract Presentation: Polyphosphate Co-Localises with FXII on Platelet-Bound Fibrin and Markedly Augments αFXIIa-Mediated Plasminogen Activation  
Speaker: Joanne L Mitchell (United Kingdom)  
14:20

Part 1: Hyperfibrinolysis in Trauma Induced Coagulopathy (TIC) - What’s Different and How Do We Manage It? Moderators: Tetsumei Urano, Japan and Waander van Heerde, The Netherlands  
Moderator: Waander van Heerde (Netherlands)  
Moderator: Tetsumei Urano (Japan)

Horse Before the Cart: Fibrinolysis in Trauma  
Speaker: Beverley Hunt (United Kingdom)  
14:35

Activation of Thrombin Activable Fibrinolysis Inhibitor (TAFI) by the Thrombin-Thrombomodulin Complex  
Speaker: Paul Kim (Canada)  
15:00

Coagulation-Dependent Initiation and Amplification of Fibrinolysis on Activated Platelets Demonstrated by Confocal Microscopy Imaging Analyses  
Speaker: Tetsumei Urano (Japan)  
15:25

Coagulopathy in a Rat Model of Traumatic Brain Injury  
Speaker: Deborah Donahue (United States)  
15:50
## Disseminated Intravascular Coagulation (DIC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>DIC-Shock Liver-Limb Necrosis Syndrome</td>
<td>Theodore Warkentin (Canada)</td>
</tr>
<tr>
<td>14:45</td>
<td>Lessons From Surveys of DIC Management Among Experts and Non-Experts</td>
<td>Alessandro Squizzato (Italy)</td>
</tr>
<tr>
<td>15:15</td>
<td>DIC Diagnosis and Management in China</td>
<td>Yu Hu (China)</td>
</tr>
<tr>
<td>15:45</td>
<td>Efficacy and Safety of Anticoagulant Therapy in Patients With Septic DIC</td>
<td>Jumpei Yoshimura (Japan)</td>
</tr>
</tbody>
</table>

## Von Willebrand Factor, Part I

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>Von Willebrand Factor and ADAMTS13: Role in Disease and Treatment,</td>
<td>Moderator: Veronica Flood (United States) and Frank Leebeek (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td>Moderators: Veronica Flood (United States) and Frank Leebeek (The Netherlands)</td>
<td>Moderator: Veronica Flood (United States) and Frank Leebeek (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td>VWF, ADAMTS13 and Animal Models of Stroke</td>
<td>Simon De Meyer (Belgium)</td>
</tr>
<tr>
<td>17:05</td>
<td>ADAMTS13 Levels and the Risk of Atherothrombosis</td>
<td>Frank Leebeek (Netherlands)</td>
</tr>
<tr>
<td>17:20</td>
<td>New Therapies Involving Recombinant ADAMTS13</td>
<td>Karen Vanhoorelbeke (Belgium)</td>
</tr>
<tr>
<td>17:40</td>
<td>Alternative Therapies for TTP</td>
<td>Jose Lopez (United States)</td>
</tr>
<tr>
<td>18:00</td>
<td>VWD Type 3, the 3WINTERS-IPS Study</td>
<td></td>
</tr>
<tr>
<td>18:20</td>
<td>Treatment of VWD with rVWF</td>
<td>Frank Leebeek (Netherlands)</td>
</tr>
<tr>
<td>18:40</td>
<td>Concluding Remarks</td>
<td>Jorge Di Paola (United States)</td>
</tr>
</tbody>
</table>

## Lupus Anticoagulant/Antiphospholipid Antibodies
The Past and Future of the Diagnostic Assays Within APS 16:45
Speaker: Philip de Groot (Netherlands)

A Novel Biophysical Approach to APS 17:15
Speaker: Jacob Rand (United States)

A Novel Model for Studying Anti-Phospholipid Antibody Interactions Using Inverted Erythrocyte Membranes 17:30
Speaker: Saartje Bloemen (Netherlands)

Dynamics of Thrombin in APS 17:45
Speaker: Romy Kremers (Netherlands)

Annexin A5 Haplotypes in the Antiphospholipid Syndrome 18:00
Speaker: Waander van Heerde (Netherlands)

Predictive Value of IgM and IgA Antiphospholipid Antibodies 18:15
Speaker: Denis Wahl (France)

Treatment and Secondary Prevention of Thrombotic APS 18:30
Speaker: Vittorio Pengo (Italy)

SSC Session 16:45 - 18:45 Antigone 1

Working Group on Perioperative Thrombosis and Hemostasis

Management of Perioperative Bleeding, Moderators: Beverly Hunt, United Kingdom and Marc Samama, France
Moderator: Beverley Hunt (United Kingdom)
Moderator: Marc Samama (France)

What Is the Role for Intra-Operative Coagulation Testing (ROTEM, TEG)? 16:45
Speaker: Beverley Hunt (United Kingdom)

Is There Any Evidenced-Based Benefit to Increase the Plasma/Platelet/Red Blood Cells Units Ratios? 17:15
Speaker: Anne Godier (France)

Fibrinogen Concentrates/Cryoprecipitates in the Bleeding Patient? 17:45
Speaker: Marc Samama (France)

Any Room for Prothrombin Complex Concentrates for the Treatment of Massive Hemorrhage? 18:15
Speaker: Simon Stanworth (United Kingdom)

SSC Session 16:45 - 18:45 Antigone 3

Pediatric and Neonatal Thrombosis and Hemostasis
Rondelet
Fibrinolysis
The haemorrhagic complications of trauma. Systemic hyperfibrinolysis is a leading cause of mortality in trauma induced coagulopathy (TIC). Approximately 80% of bleeding-related mortality occurs within the first 24 h from injury, with a median time to death of 2 h. A four-fold higher mortality is associated with those patients exhibiting trauma induced coagulopathy (TIC). TIC has been attributed to numerous defects in coagulation, including depletion of coagulation factors, fibrinogen depletion, platelet dysfunction, and systemic hyperfibrinolysis. The most fatal phenotype in TIC is hyperfibrinolysis, with a mortality rate ranging from 60-90%. Despite the direct association of hyperfibrinolysis with mortality in TIC the basic mechanisms underpinning the pathogenesis of this condition are relatively poorly understood. There is also extensive debate over the best way to treat patients with TIC. Current recommendations vary in different countries and include administration of blood products in 1:1:1 ratio, the use of tranexamic acid (a focus of the recent CRASH trial) and fibrinogen concentrate. This SSC session will focus on the main questions in the field of hyperfibrinolysis in TIC. The meeting will be divided into basic, translational and clinical sessions with key speakers with background in the field in each section. There will also be a discussion at the end of the SSC session to draw out the key topics that should be addressed in the immediate future and the potential role for the SSC in aiding this process.

Part 2: Hyperfibrinolysis in Trauma Induced Coagulopathy (TIC) - What’s Different and How Do We Manage It? Moderators: Paul Kim, Canada and Nicola Mutch, United Kingdom
Moderator: Nicola Mutch (United Kingdom)
Moderator: Paul Kim (Canada)

Enhanced Primary Fibrinolysis Is the Predominant Cause of Post Trauma Bleeding and Coagulopathy
Speaker: Robert Medcalf (Australia)
### Scientific Schedule & Program

**The Incidence of Fibrinolysis in Multiple Trauma Identified With the Cartridge Thromboelastography (TEG6s): A Spectrum of Fibrinolytic Phenotypes**  
Speaker: Mark Walsh (United States)  
17:35

**The Role of Fibrinogen in Acute Traumatic Coagulopathy**  
Speaker: Nicola Curry (United Kingdom)  
18:00

**Discussion - Key Questions & Future Directions in TIC**  
18:25

### SSC Session  
16:45 - 18:45  
Barthez

**Disseminated Intravascular Coagulation (DIC)**

**The Role of Antiplatelet Therapy in Sepsis**  
Speaker: Bernd Jilma (Austria)  
16:45

**Thromboelastography - Practicalities in DIC Diagnosis**  
Speaker: Thorsten Brenner (Germany)  
17:10

**Neutralizers of Histones and DAMPS in DIC**  
Speaker: Toshiaki Iba (Japan)  
17:35

**DAMPs and DIC - Standardisation**  
Speaker: Sacha Zeerleder  
18:00

**Is DIC Not Much of a Problem Anymore?**  
Speaker: Jecko Thachil (United Kingdom)  
18:25

### Poster Session and Networking

**Endothelial Injury and Hypoxia Enhances Neutrophil Recruitment, Extravasation, and Apoptosis during Thrombus Formation**  
Speaker: Satoshi Nishimura (Japan)  
19:00 - 21:00  
Joffre 1-3

**TMEM16F-Mediated Platelet Pro-Coagulant Activity Contributes to Infarct Progression after Ischemic Stroke**  
Speaker: Ayesha Anjum Baig (Germany)

**Time-Dependent Decay of mRNA, Ribosomal RNA and Translation Activity in Platelets**  
Speaker: Catherine Angénéieux (France)

**Platelets Promote MMP-Dependent Plaque Destabilization Locally at the Site of Vascular Injury**  
Speaker: Tom Mastenbroek (Netherlands)

**Genetic or Pharmacologic Depletion of Platelet Serotonin Attenuates Myocardial Ischemia Reperfusion Injury**  
Speaker: Maximilian Mauler (Germany)
Lack of Endothelial Nitric Oxide Synthase (eNOS) Induces a Pro-Thrombotic Phenotype in Mice  
Speaker: Stefania Momi (Italy)

Microparticles Derived from Ovarian Cancer Cell Line Contained Genomic and Biologically Active Proteins, Including Tissue Factor Involved in Coagulation  
Speaker: Samaher Besbes (France)

Hemostatic Disturbances and Oxidative Stress in Experimental Bothrops jararaca Envenomation: Modulation by the Natural Antioxidant Quercetin-3-Rutinoside (Rutin)  
Speaker: Marcelo Larami Santoro (Brazil)

Expression of Heparanase in Cancer as Biomarker of Malignancies: Overexpression in an Aggressive, Poor Survival Gastric Cancer “Gastric Signet Ring Cell Carcinoma” Compared with that of Other Gastric Cancers  
Speaker: Caroline Fourgeaud (France)

Acquired von Willebrand Syndrome Evoked by Experimental Bothrops jararaca Envenomation  
Speaker: Marcelo Larami Santoro (Brazil)

Patagonfibrase Modifies Protein Expression of Tissue Factor and Protein Disulfide Isomerase in Rat Skin  
Speaker: Marcelo Larami Santoro (Brazil)

Algogenic Compounds Found in Rat Platelet Releasate  
Speaker: Marcelo Larami Santoro (Brazil)

Variegin: Pharmacokinetics and Pharmacodynamics  
Speaker: Norrapat Shih (Singapore)

Aminoestrogen Diebud Decreases Circulating Microparticles  
Speaker: Mirthala Flores-Garcia (Mexico)

Microfluidic Platform for Automated Endothelial Cell Culture Enabling Real Time Visualisation of Blood Cell Function under Flow  
Speaker: Crispin Szydzik (Australia)

Occlusive Thrombus Growth at High Shear Rates: Comparison of Whole Blood and Platelet Rich Plasma at Constant Pressure  
Speaker: Shunichi Kobayashi (Japan)

Shear-Dependent Red Blood Cell and Platelet Adhesion in Sickle Cell Disease  
Speaker: Erdem Kucukal (United States)

Clot-Bound Thrombin under Venous Flow Conditions  
Speaker: Laura M Haynes (United States)

Hemorheologic Bases for Thrombosis in Some Myeloproliferative Neoplasms  
Speaker: Eugene Roitman (Russian Federation)

Thrombus Structure Change under Various Shear Rate, Using a Novel Microfluidic Device  
Speaker: Hideo Hirakata (Japan)

Effect of Extremes of Body Weight on Efficacy and Safety of Rivaroxaban in the Treatment of Venous Thromboembolism; Real Life Experience  
Speaker: Deepa Jayakody Arachchillage (United Kingdom)
Scientific Schedule & Program

VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban - A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin
Speaker: C. Michael Gibson (United States)

Improving Clinical Management of VTE: Simulation in Continuing Education
Speaker: Jelena Spyropoulos (United States)

Genetic Dosing Algorithm Underestimates the Warfarin Dose Requirement Among Patients Having Severe Thrombosis or Thrombophilia
Speaker: Tuukka Helin (Finland)

Impact of Apixaban on the Dilute Russell’s Viper Venom Time: An Ex-vivo Study
Speaker: Anne-Laure Sennesael (Belgium)

Choosing Wisely: The Impact of Inclusion and Exclusion Criteria on Efficacy and Safety Outcomes in EINSTEINDVT/PE and AMPLIFY
Speaker: Jan Beyer-Westendorf (Germany)

Optimizing Therapy for Vitamin K Antagonist Induced Major Hemorrhage: A Systematic Review
Speaker: Samuel Abegunde (Nigeria)

The Effect of Andexanet Alfa on the Pharmacokinetics and Renal Clearance of the Direct Factor Xa Inhibitors Apixaban, Rivaroxaban, Edodoxaban and Betrixaban
Speaker: Janet M. Leeds (United States)

Prothrombin Conversion and Thrombin Inactivation in Patients Anticoagulated with Enoxaparin, Vitamin K Antagonists, and Rivaroxaban
Speaker: Romy Kremers (Netherlands)

Individual Variability of Plasma with Edoxaban on the Fibrin Structure as a Function of Blood Donors
Speaker: Olivier Mathieu (France)

Accuracy of the Louzada Prediction Rule for Recurrent VTE in Cancer Patients on Rivaroxaban for the Treatment of Venous Thromboembolic Disease
Speaker: Melissa Forgie (Canada)

Early Changes in Medication Beliefs, Illness Perceptions and Anticoagulation Related Quality of Life in Patients Poorly Controlled on Vitamin-K Antagonists (VKAs) Switched to a Direct Oral Anticoagulant (DOAC) – Results from the SWITCHING Study
Speaker: John Kyrillos Abdou (United Kingdom)

Analysis of Heparin Induced Thrombocytopenia Screening Tests in Critical Care Units
Speaker: Osamah Khojah (Saudi Arabia)

Post Analytical External Quality Assessment (EQA) for Computerised Decision Support Software (CDSS) Employed for INR Dosing
Speaker: Dianne Patricia Kitchen (United Kingdom)

External Quality Assurance Provision (EQA) for the Point of Care Xprecia Stride INR Device
Speaker: Dianne Patricia Kitchen (United Kingdom)

An Ultrasound-based Sensor for Real-time Monitoring of Heparin Anticoagulation Therapy
Speaker: Jesse Jokerst (United States)
**Scientific Schedule & Program**

**Inclusion of a Heparin Neutralizer in the Plasma Diluent Confers Specificity to the FXa Direct Oral Anticoagulants Rivaroxaban, Apixaban, and Edoxaban in an Anti-Xa Chromogenic Assay**
Speaker: Duy Nguyen (United States)

**Influence of Factor VII on INR Determined with Recombinant Human and Tissue-Extract Thromboplastins**
Speaker: Joseph Biedermann (Netherlands)

**The Effect of Dabigatran on Thrombin Generation in vitro**
Speaker: Willemijn Comuth (Denmark)

**Commutability of Samples Used to Assess Assays for Direct Oral Anticoagulants (DOACS): Data from UK NEQAS for Blood Coagulation Multicentre Studies**
Speaker: Ian Jennings (United Kingdom)

**Is the Dilute Russell’s Viper Venom Time (DRVV-T) a Useful Assay for All Direct Oral Anticoagulants (DOACs)?**
Speaker: Miren Gabilondo (Spain)

**Outcome of DOAC Exposure during Pregnancy ...and the Problem of Event Reporting...**
Speaker: Jan Beyer-Westendorf (Germany)

**Consequences of Warfarin Suspension after Major Bleeding in a Cohort of Very Elderly Patients**
Speaker: Giacomo Zoppellaro (Italy)

**Assessment of Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Results from the TRIVET Study**
Speaker: Mark Crowther (Canada)

**Major Bleeding in Patients with Atrial Fibrillation on Non Vitamin K Antagonist Oral Anticoagulants - Data from Ljubljana Registry**
Speaker: Nina Vene (Slovenia)

**Patients Anticoagulation Knowledge (VKA) and INR Goal Attainment-Comparison 2014 and 2016**
Speaker: Violeta Jovanoska (Macedonia, the Republic of)

**Can PT, aPTT and TT Reliably Be Used to Detect DOAC at Clinically Relevant Concentrations in Emergency Situations? Results from a 660-Patient Cohort Study**
Speaker: Virginie Siguret (France)

**Effectiveness of Implementing an Extended INR Testing Interval for Stable Warfarin Patients: Results from the MAQI2 Collaborative of Anticoagulation Clinics**
Speaker: Geoffrey Barnes (United States)

**Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting with or without Heparin Bridging: An Ex vivo Study Using Dedicated Chromogenic Assays**
Speaker: Sarah Lessire (Belgium)

**Self-testing and Self-management of Oral Anticoagulation Therapy (OAT) in Children with Congenital Heart Disease (CHD). From the Bedside to Home. A Pilot Study in Spain**
Speaker: Laura López Andreoni (Spain)

**Venous Thromboembolism Treatment with Rivaroxaban in Adolescents - Preliminary Findings from the Prospective Dresden NOAC Registry (NCT01588119)**
Speaker: Jan Beyer-Westendorf (Germany)
Scientific Schedule & Program

In vivo and Ex vivo Effect of Various Rivaroxaban Concentrations on Thrombin Generation
Speaker: Debora Bertaggia Calderara (Switzerland)

Evaluation of the CP3000 Coagulation Analyzer
Speaker: Johannes Hoffmann (Netherlands)

Evaluation of the Intra-, Inter- and Day-to Day Variability of the ROTEM®
Speaker: Petra Jilma (Austria)

Quality Assurance in a Haemostasis Laboratory - An Evaluation of Seven Year Quality Indicator Data Utilizing Sigma Metrics
Speaker: Muhammad Sharig Shaikh (Pakistan)

Propagation of Thrombin Generation in Space Reveals Difference in Effects of Heparin, Dabigatran and Rivaroxaban
Speaker: Natalia Dashkevich (Russian Federation)

A Performance Evaluation of a Novel Human Recombinant Tissue Factor Prothrombin Time Reagent
Speaker: Chris Gardiner (United Kingdom)

The Control of Heparin Treatment with Global Hemostasis Assays: A Sensitivity Analysis
Speaker: Anna Balandina (Russian Federation)

Evaluation of Laboratoricaly Monitored Efficiency of New Oral Anticoagulants Rivaroksaban and Dabigatran
Speaker: Marija Šega (Slovenia)

Measuring Direct Oral Anticoagulants in Standardized Fully Automated Thrombin Generation on Ceveron® Alpha
Speaker: Nikolaus B. Binder (Austria)

Distinct Effects of Apixaban and Rivaroxaban on Thrombin Generation and Coagulation during Recovery after Total Hip Arthroplasty
Speaker: Tuukka Helin (Finland)

Performance of a New Chromogenic Apixaban Assay on Automated Analyzers
Speaker: Zhenghua Cao (United States)

Safety and Efficacy of Dabigatran Compared with Warfarin in Patients with Acute Venous Thromboembolism Enrolled in RE-COVER®/ RE-COVER II™ in Western Europe
Speaker: Martin Feuring (Germany)

Efficacy and Safety of Dabigatran versus Warfarin for the Treatment of Acute Venous Thromboembolism: a Pooled Analysis of 90-Day Data from RE-COVER™ and RE-COVER™ II
Speaker: Martin Feuring (Germany)

Application of Basic and Special Coagulation Tests for Measuring Rivaroxaban Activity
Speaker: Rosa Vidal Laso (Spain)

EffectiVeness and Safety of Rivaroxaban Therapy in Daily-Care Patients with Unusual Venous Thromboembolism - Results of the Prospective Dresden NOAC Registry (NCT01588119)
Speaker: Jan Beyer-Westendorf (Germany)

Reasons and consequences of Vitamin K Antagonists (VKA) Discontinuation in Very Elderly Patients with Non Valvular Atrial Fibrillation (NVAF). An Inception Cohort Study
Speaker: Giacomo Zoppellaro (Italy)
The Frequency of Gene Polymorphism among Patients with Hemorrhagic Complications Connected with Warfarin Therapy  
Speaker: Olga Philippova (Russian Federation)

Prescribing Errors with New Oral Anticoagulants at a Regional Base Hospital in NSW, Australia  
Speaker: David Glendinning (Australia)

Comparison of Locally Measured Activated Partial Thromboplastin Time (aPTT) to Central Laboratory aPTT when Measuring Reversal of Dabigatran Using Idarucizumab  
Speaker: Jeffrey I. Weitz (Canada)

Warfarin as a New Oral Anticoagulant Agent?  
Speaker: Pall T. Onundarson (Iceland)

Comparing Mechanisms of Action of Novel Anticoagulant Reversal Agents through Studies on Binding Partners and on Clot Formation and Clot Structure  
Speaker: Charles Haynes (Canada)

Matrix Effect of Commercially Available Direct Oral Anticoagulant Standards: A Look through the Limits and the Need for Standardization of Current Calibrators  
Speaker: Jonathan Douxfils (Belgium)

Concentration Dependent Effects of Edoxaban on Thrombin Generation Kinetics and Physical Clot Characteristics by TEG 6S and CAT Assay  
Speaker: Udaya Tantry (United States)

Acute Ischemic Stroke after Administration of Kcentra for Apixaban-associated Intracranial Hemorrhage  
Speaker: Navdeep Lail (United States)

Unusual Site Thrombosis - Epidemiology and Outcome  
Speaker: PRAVAS CHANDRA Mishra (India)

A Comparative Study Using Four Different Clot Detection Methods for INR Monitoring in Patients on Vitamin K Antagonist Treatment  
Speaker: Alex Gatt (Malta)

Warfarin Dose Assessment Every 4 Weeks versus Every 6 to 8 Weeks in Patients with Stable International Normalized Ratios: A Retrospective Study  
Speaker: Siavash Piran (Canada)

Development of an INRRIIVA on Plasma Samples of Patients on Rivaroxaban  
Speaker: James Zhang (Canada)

Length of Anti-Coagulation in Splanchnic Venous Thrombosis  
Speaker: M.Shehazad Sarwar (Pakistan)

A Different Clinical Profile of DOAC-Treated Patients: Results from the Real Life Cohort Study  
Speaker: Miren Gabilondo (Spain)

Rivaroxaban Therapy for Patients with Pulmonary Embolism in Real World: A Prospective, Single Center, Open-label Observation Study  
Speaker: Tian-Yu Lian (China)
Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC)
Speaker: Trung Nguyen (United States)

Histones Released from Extracellular Nucleosomes upon Dnase Digestion Are Rapidly Degraded by Factor VII Activating protease (FSAP) to Combat Their Cytotoxic Effects
Speaker: Sacha Zeerleder

Laboratory Tests as Clues to Understand the Etiopathogenesis of Hemostatic Disturbances, Acute Kidney Injury and Mild Intravascular Hemolysis in Bothrops Envenomation
Speaker: Marcelo Larami Santoro (Brazil)

Tissue Factor Initiated Thrombin Generation in Trauma Patient Plasma
Speaker: Saulius Butenas (United States)

Circulating Histone as a Marker of Cardiovascular Failure in Patients with Sepsis
Speaker: Takashi Ito (Japan)

Coagulopathy Assessment in Severe Sepsis and Septic Shock Patients. An Observational Pilot Study
Speaker: Ecaterina Scarlatescu (Romania)

Coagulation Changes in Porcine Model of Sepsis Induced by Methicillin-Resistant Staphylococcus aureus (MRSA) Inoculation: Correlation between ROTEM and Routine Laboratory Tests
Speaker: Jun Teruya (United States)

Hyaluronic Acid Decreases the Mechanical Stability, but Increases the Lytic Resistance of Fibrin
Speaker: Krasimir Kolev (Hungary)

Thrombolysis - Proteolysis - Isopeptidolysis
Speaker: Sergey Kalabushev (Russian Federation)

Polyphosphate Co-Localises with FXII on Platelet-Bound Fibrin and Markedly Augments αFXIIa-Mediated Plasminogen Activation
Speaker: Joanne L Mitchell (United Kingdom)

Recombinant Human ADAMTS13: First-in-Human Study Evaluating Pharmacokinetics, Safety and Tolerability in hTTP Patients
Speaker: Marie Scully (United Kingdom)

The Covalent or Non-Covalent Modification of Streptokinase with Polyethylene Glycol Improves its Properties
Speaker: Roza Aisina (Russian Federation)

Inhibitory Effects of Intact Heavy Chain of Plasminogen and its Fragment K1-4.5 on the Generation of Plasmin in vitro
Speaker: Lilia Mukhametova (Russian Federation)

The Time Course of Plasma Procarboxypeptidase U (proCPU, proCPB2 or TAFI) in Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage is Not Associated with the Presence of Acute Coagulopathy
Speaker: Dorien Leenaerts (Belgium)

Procarboxypeptidase U (proCPU, TAFI, proCPB2) in Cerebrospinal Fluid (CSF) in the Hyperacute Phase of Ischemic Stroke
Speaker: Joachim C Mertens (Belgium)
Scientific Schedule & Program

Local Hemostasis Changes and Endothelial Damage during Percutaneous Transcatheter Isolation of the Pulmonary Veins in Patients with Atrial Fibrillation
Speaker: Zsuzsa Bagoly (Hungary)

Thrombin Activatable Fibrinolytic Inhibitor (TAFI) Increases in the Plasma of Cancer Patients with Pro-Thrombotic Behavior
Speaker: Juan-Carlos Murciano (Spain)

Combinatorial Therapy with C1 Esterase Inhibitor and Tranexamic Acid to Treat Hemorrhagic Shock
Speaker: Veronika Bade (Russian Federation)

Effect of Elapsed Time between Plasma Separation and Processing on Fibrinolytic Activity
Speaker: Alicia N. Blanco (Argentina)

Longitudinal Analysis of Coagulant and Fibrinolytic Markers of Trauma Patients that Received Tranexamic Acid
Speaker: Maria Cristina Bravo (United States)

INSIGHT Case-Control Study: High FVIII Concentrate Dose and Surgery Are Associated with Increased Inhibitor Risk in Nonsevere Hemophilia A Patients
Speaker: C.J. Fijnvandraat (Netherlands)

FVIII-LRP1 Interaction affinity is Biased by FVIII Concentration
Speaker: Michael Dockal (Austria)

Variation in Baseline Factor VIII Concentration in Mild and Moderate Hemophilia A Patients Carrying the Same F8 Mutation
Speaker: Janneke Loomans (Netherlands)

A Retrospective Study of the Current Treatment Practice of Haemophilia A and B in France
Speaker: Stefan Lethagen (Sweden)

Non-Neutralizing Antibodies against Factor VIII and the Risk of Inhibitor Development in Untreated and Minimally Treated Patients with Severe Hemophilia A (SIPPET Study)
Speaker: Antonino Cannavo (Italy)

Immunological Profile of Previously Untreated Patients with Haemophilia A: Results from the HEMFIL Study
Speaker: Leticia Lemos Jardim (Brazil)

Thrombin Generation Assay (TGA) for Monitoring the Haemostatic Response in Patients with Hemophilia and Inhibitors on Immune Tolerance Induction (ITI): Preliminary in vitro and in vivo Results from the PredicTGA Study
Speaker: Elena Santagostino (Italy)

Importance of Standardized Joint-Ultrasound for Individualization of Prophylaxis in Hemophiliacs: Easy-to-Learn-Ultrasongraphy (HEAD-US) of Joints and Correlation with Function in Haemophilic Arthropathy - Results of a Clinical Trial
Speaker: Michael Sigl-Kraetzig (Germany)

Evaluation of the Efficiency of Immunotolerance in Hemophilia A: Preliminary Results of the Brazilian Immunotolerance Study
Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)

A Novel Factor VIII-Nanobody Fusion Protein Displaying Prolonged Half-Life & Haemostatic Efficacy in vivo
Speaker: Vincent Muczynski (France)
ELISA Combined Chromogenic Assay (ECA) for Determination of Binding of PEGylated rFVIII to VWF  
Speaker: Michael Dockal (Austria)

The Patient Reported Outcome Burdens and Experiences (PROBE) Study - Phase 1 Results Show PROBE Study Methodology Feasible  
Speaker: Mark Skinner (United States)

The Relationship between Thrombin Generation and Spontaneous Bleeding for Hemophilia a Subjects in A-LONG and Extension Study  
Speaker: Yang Buyue (United States)

Internal Consistency and Item-Total Correlation of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People with Hemophilia (PWH): Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study  
Speaker: Michael Wang (United States)

Known-Group Validity of Patient-Reported Outcome (PRO) Instruments and Hemophilia Joint Health Score v2.1 (HJHS) in US Adult People with Hemophilia (PWH): Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study  
Speaker: Tyler W. Buckner (United States)

HLA Genotyping and Factor VIII Intron 22 Inversion in Children with Severe Haemophilia A: Relation to Factor VIII Inhibitor Development  
Speaker: Helen Platokouki (Greece)

Clinical Decision Making is Effective in Reducing Bleeding Rates without the Need to Monitor FVIII trough Levels in Patients with Severe Hemophilia A Receiving Prophylaxis with rVIII-SingleChain  
Speaker: Alex Veldman (Germany)

Introduction of a Standardised Heat Inactivated Nijmegen - Bethesda Assay (NBA) for the Detection and Quantification of FVIII Inhibitors  
Speaker: Tracey Noon (Ireland)

Isolation of Antibodies that Differentiate Between Wild-Type FIX and the Padua Variant  
Speaker: Hanspeter Rottensteiner (Austria)

Development and Application of a FIX-Specific Immunoassay to Monitor Hemophilia B Gene Therapy  
Speaker: Hanspeter Rottensteiner (Austria)

Benefit of the Study of F8 Gene Transcription by in vitro, in vivo and in silico Analysis in Hemophilia A  
Speaker: Catherine Costa (France)

Method-Related Potency Issues of Modified Factor VIII Products  
Speaker: Sarah Daniels (United Kingdom)

Individualizing Hemophilia Prophylaxis Using Thromboelastography (HIP TEG)  
Speaker: Guy Young (United States)

Product-Specific Calibration Standards Do Not Correct One-Stage Clotting Assay Discrepancies for Modified Recombinant FIX Molecules with Reagents that Significantly over- or under-Recover Labeled Potency  
Speaker: Yang Buyue (United States)
Bleeding Scores in Hemophilia: Are They Useful in Predicting Severity and Clinical Outcomes
Speaker: Munira Borhany (Pakistan)

Thrombin Generation Does Not Correlate with Disease Severity but May Be Predictive of Response to Treatment in Patients with Severe Hemophilia A
Speaker: Ruchika Sharma (United States)

Prophylaxis with Factor-Eight-Inhibitor-by-Passing-Activity Three Days a Week Results in Safe and Effective Haemostasis in Children with Haemophilia A with Inhibitors
Speaker: Mark Bellettrutti (Canada)

Results From a World-Wide Field Study of FVIII Activity Assay Variability of BAX 855, the PEGylated form of rFVIII ADVATE, in Clinical Hemostasis Laboratories
Speaker: Peter L. Turecek (Austria)

Reagents Causing N9-GP Underestimation in One-Stage FIX Clot Method Inhibit FXIa-Catalysed FIX Activation and Discriminate between N9-GP and FIX in Plasma Independently of Contact Activation and Phospholipid
Speaker: Egon Persson (Denmark)

Multi-National Survey of FVIII Activity Assay Practice
Speaker: Peter L. Turecek (Austria)

Effects of Haemolysis, Icterus and Lipaemia on Coagulation Tests as Performed Using Mechanical Viscosity Based Endpoint Detection
Speaker: Anita Woolley (United Kingdom)

Mutational Analysis in 18 Pakistani Families with Haemophilia B: Identification of a Novel Mutation
Speaker: Muhammad Tariq Masood Khan (Pakistan)

Qualification of Selected One-Stage APTT and Chromogenic Assays for the Post-Administration Monitoring of Nonacog Beta Pegol
Speaker: Stefan Tiefenbacher (United States)

Diagnosis and Management of Acquired Haemophilia - Single Centre Experience
Speaker: Peter Salaj (Czech Republic)

Turkish Experience with Low Dose of Immun Tolerance Treatment for Inhibitor Patients
Speaker: Kaan Kavakli (Turkey)

Haemophilia A and Immune Tolerance Induction - Our First Experiences
Speaker: Marian Fedor (Slovakia)

N9-GP Activity Can Be Measured using Select One-Stage Clot Assays and Two-Stage Chromogenic Assays in Clinical Samples from Adults/Adolescents and Children with Haemophilia B
Speaker: Guy Young (United States)

Factor VIII Effect and Sensitivity Vary Depending on Trigger in Thrombin Generation Assays with Plasma from Patients with Hemophilia A
Speaker: Michael Dockal (Austria)

High Agreement Rate between Ellagic Acid-Based One Stage and Chromogenic Assays for rFVIIIFc Post Infusion Samples in the A-LONG Study
Speaker: Claire Pouplard (France)
A Simple Predictive Model of Thrombin Generation for the Individualization of Hemophilic Treatment
Speaker: Pierre Chelle (France)

Effectiveness of Heat Inactivation in Removing Residual FVIII Interference in the FVIII Nijmegen Bethesda Assay
Speaker: Mary Robinson (United States)

Haemolysis Effects on Clotting Factor and Thrombotic Assay Results using Matched Haemolysed and Non-Haemolysed Patient Samples and Two Artificial Haemolysis Mechanisms
Speaker: Paula Brown (United Kingdom)

Application of Rox Factor IX on the ACL TOP 700
Speaker: Pia Bryngelhed (Sweden)

The Utility of ISTH BAT in Assessing the Bleeding Phenotype in Patients with FV Deficiency
Speaker: Munira Borhany (Pakistan)

Application of Global Coagulation Assays in Hemophilia B Patients to Evaluate the Hemostatic Potential in Baseline Conditions and after FIX Concentrate Administration
Speaker: Cristina Santoro (Italy)

The Development of Arterial Thrombosis in Hemophilia A - Unusual Coincidence? Case Report and Review of the Literature
Speaker: Lucia Stanciakova (Slovakia)

Managing Hemophilia Treatment in Algeria, the Experience of Constantine
Speaker: Sihem Kebaili (Algeria)

Epidemiological Study of Hemophilia at Tlemcen University Hospital (Algeria)
Speaker: Hanane Bezzou (Algeria)

Potency Estimates for Recombinant Factor IX in the One-Stage Clotting Assay Are Influenced by More than Just Choice of APTT Reagent
Speaker: Helen Wilmot (United Kingdom)

Calcium Chloride Reagent Regulates Thrombin Generation Response of Hemophilia Plasma to Factor Concentrate Treatments
Speaker: Mikhail Ovanesov (United States)

Inherited Bleeding Disorders: An Experience from a Tertiary Care Centre in South India with Emphasis on an Algorithmic Approach to Diagnosis
Speaker: Rakhee Kar (India)

A New Comprehensive Screening Program for Optimizing the Diagnosis of Coagulopathies in a Tertiary Hospital
Speaker: Veronica Pons (Spain)

Distraction Arthroplasty in Patient with Hemophilic Arthropathy (A Case Report)
Speaker: Maria Hulíkova (Slovakia)

Novel Mechanisms Regulating Factor XI Plasma Levels
Speaker: Maria Sabater-Leal (Sweden)

Plasma Kallikrein Contributes to Tissue Plasminogen Activator (tPA) Therapy-Induced Brain Injury during Thrombotic Stroke
Speaker: Fabricio Simão (United States)
Role of Plasma Kallikrein-Kinin System in the Pathogenesis of Ambient Particulate Matter-Induced Lung Injury  
Speaker: Bo Wang (China)

Assessment of Small Molecular Weight Inhibitors of the Contact Pathway  
Speaker: Charlotte Bouckaert (Belgium)

Copurification of Polyphosphate with Nucleic Acids May Contribute to the Procoagulant Activity of DNA and RNA  
Speaker: Stephanie Smith (United States)

Correlation between the Thrombogenic Factor Xla and the Thrombus Score in the Venous Stasis Rabbit Model  
Speaker: Charles-Edouard Laurent (Canada)

Procoagulant Activity in Immunoglobulin Products  
Speaker: Stella Williams (United Kingdom)

Investigation of Possible Correlation between Clinical and Laboratory Phenotype in Congenital FXI Deficiency: Results from a Single Center  
Speaker: Cristina Santoro (Italy)

Structure and Function Consequences of a Novel Missense Mutation in FGB Gene (ββ Gly272Arg/p.Gly302Arg) Resulting in Afibrinogenemia  
Speaker: German Detarsio (Argentina)

Visual Quantification of Fibrin Network Density  
Speaker: Joke Konings (Netherlands)

Development and Evaluation of Total and Free Factor XIII-B Subunit ELISA Methods  
Speaker: Eva Katona (Hungary)

FXIII Activity and Antigen during Pregnancy  
Speaker: Mario von Depka (Germany)

Thromboelastography (TEG) and Thrombin Generation Assay (TGA) in Congenital Afibrinogenemia  
Speaker: Viridiana Cano Garcia (United States)

Clinical and Molecular Characteristics of Patients Affected by Congenital Fibrinogen Deficiency  
Speaker: Munira Borhany (Pakistan)

Automated Fibrin Structure Assay: Determination of Normal Range  
Speaker: Christophe Martinaud (France)

Characterization of Phenotypic Expression of Inherited Fibrinogen Coagulopathy in Pakistani Index Patients  
Speaker: Tehmina Nafees Sonia Khan (Pakistan)

Functional/Antigen Fibrinogen Ratio in Different Clinical Situations  
Speaker: Alicia N. Blanco (Argentina)

Molecular Modelling of Identified Six Novel Missense Mutations in Pakistani Congenital Afibrinogenemia Patients  
Speaker: Tehmina Nafees Sonia Khan (Pakistan)
Diagnosis of Inherited Platelet Disorders by a Panel-Based Next Generation Sequencing Approach  
Speaker: Harald Schulze (Germany)

Design and Application of a Twenty-Three-Gene Panel by Next-Generation Sequencing for Inherited Coagulation Bleeding Disorders  
Speaker: Jose Maria Bastida (Spain)

Utilizing the Strength of Pedigree-Based Study Design to Identify Novel tPA Loci  
Speaker: Nora Zwingerman (Canada)

ThromboGenomics: A comprehensive High-Throughput Sequencing Test for the Diagnosis of Inherited Bleeding, Thrombotic and Platelet Disorders  
Speaker: Kate Downes (United Kingdom)

Improved Venous Thromboembolism Risk Assessment with a Multilocus Genetic Risk Score  
Speaker: Grigoris T Gerotziafas (France)

Identifying the Genetic Basis of Rare Bleeding and Platelet Phenotypes Using Systematic Phenotyping and Genome Sequencing  
Speaker: Michael Laffan (United Kingdom)

FVII Deficiency and Thrombosis, Coincidence or New Mechanism of Thrombophilia  
Speaker: Yacine Larfi (Algeria)

Identification of Molecular Defects in ITGA2B and ITGB3 Genes and Phenotypic Correlation in Pakistani Patients with Glanzmann Thrombasthenia  
Speaker: Muhammad Younus Jamal Siddiqi (Pakistan)

A Novel Nonsense Mutation Glu326* of PROS1 Leading to ProS Deficiency  
Speaker: Bei Hu (China)

Identification of Two Novel Single Nucleotide Variants of the Complement Factor H (CFH) and Factor I (CFI) Genes in a Familial Form of Atypical Hemolytic Uremic Syndrome (aHUS)  
Speaker: Célia Dos Santos (Argentina)

High Prevalence of VKORC1*3 (G9041A) Genetic Polymorphism in North Indians: A Study on Patients with Cardiac Disorders on Acenocoumarol  
Speaker: TUSHAR Sehgal (India)

Clinical Profile of Patients with Proximal Deep Venous Thrombosis Patients – A Prospective Observational Study from a Tertiary Care Hospital in North India  
Speaker: Vikas Suri (India)

Aspirin Inhibits Colon Cancer Cell Proliferation through Synergistic Suppression of NF-κB and c-MYC Oncoproteins  
Speaker: Annachiara Mitrugno (United States)

Platelets Upregulate c-MYC Oncoprotein in Pancreatic Cancer Cells: Potential Mechanism of Platelet-Driven Neoplastic Proliferation  
Speaker: Annachiara Mitrugno (United States)

Optimal Doses of Tinzaparin to Reduce Both Cancer-Associated Thrombosis and Tumor Growth in a Mouse Model of Ectopic Pancreatic Syngeneic Tumor  
Speaker: Christophe Dubois (France)
A Comparison of Cancer Types and the Epidemiology of First Venous Thromboembolism in Patients with Active Disease
Speaker: Alexander Thomas Cohen (United Kingdom)

Fibrin Structure Assay: A New Diagnostic Tool in the Management of Cancer
Speaker: Elodie Beulin (France)

Thromboembolic Events (TE) in Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Treated with Platinum-based Chemotherapy
Speaker: Victoria Castellón-Rubio (Spain)

Cardiovascular Effect of BCR-ABL TKIs: A Meta-Analysis and Systematic Review of Arterial and Venous Occlusive Events
Speaker: Hélène Haguet (Belgium)

Effects of Androgen Deprivation Therapy on Hypercoagulability in Prostate Cancer Patients - A Prospective Longitudinal Study
Speaker: Maha Othman (Canada)

Diagnostic Performance of Hemostatic Biomarkers in Cancer Patients
Speaker: Elina Beleva (Bulgaria)

Evaluation of Thromboelastography (TEG) in Patients with Myeloproliferative Neoplasm (MPN): Platelet Count > 600 Associated with Prothrombotic Parameters
Speaker: Prahlad Ho (Australia)

Cancer, Chronic Kidney Disease and Thrombosis
Speaker: Ismail Elalamy (France)

Thromboprophylaxis for Prevention of Venous Thromboembolism in Patients with Multiple Myeloma - A Systematic Review and Metaanalysis
Speaker: Deepa Suryanarayan (Canada)

Risk Assessment of Venous Thromboembolism (VTE) and Thromboprophylaxis in Pregnant Women Hospitalized with Cancer
Speaker: Venina Barros (Brazil)

Tissue Factor Positive Microparticles Remain Undetectable by Flow Cytometry in Pleural Fluids from Cancer Patients Despite High Level of Procoagulant Activity
Speaker: Philippe Poncelet (France)

Microparticle-Tissue Factor Activity as Biomarker for Excluding Thrombosis in Acute Leukemic Patients: Comparison of Three Assays
Speaker: Damien Gheldof (Belgium)

Short- and Long-Term Mortality after Pulmonary Embolism in Patients with and without Cancer
Speaker: Ghazi Alotaibi (Canada)

Impedance Platelet Aggregometry for Surveillance of Ibrutinib Therapy in Chronic Lymphocytic Leukaemia
Speaker: Will Thomas (United Kingdom)

Platelet Transfusion Practices in Adult Surgical, Haematology and Oncology Patients
Speaker: Anila Rashid (Pakistan)
Platelet-Derived Factor V is an Important Determinant of the Metastatic Potential of Circulating Tumor Cells  
Speaker: Xin Deng (China)

The Hypercoagulable Profile of Patients with Myeloproliferative Neoplasms (MPN) as Detected by Whole Blood Rotational Thromboelastometry (ROTEM)  
Speaker: Cinzia Giaccherini (Italy)

Thrombosis in Myeloproliferative Neoplasia Associated with Different Coagulation Factor Polymorphisms  
Speaker: Rūta Dambrauskiené (Lithuania)

Evaluation of Mean Platelet Volume as a Predictive Marker for Venous Thromboembolism in Patients Treated for Hodgkin Lymphoma  
Speaker: Joanna Rupa-Matysek (Poland)

Risk Factors Assessment for Thrombosis in Patients with Cancer - Research Project of the Federal University of Minas Gerais  
Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)

Frequency and Management of Venous Thrombosis in Adult Acute Leukemia Patients at a Tertiary Care Hospital of Pakistan  
Speaker: M. Shahzad Sarwar (Pakistan)

Contribution of Modelling of Procoagulant Properties of Cancer Cells in the Understanding of Their Mechanisms of Action and the Effectiveness of Anticoagulant Agents  
Speaker: Grigoris T Gerotziafas (France)

Inverted Erythrocyte Membranes as a Novel Model for Studying the Antiphospholipid Syndrome  
Speaker: Saartje Bloemen (Netherlands)

Pravastatin Ameliorates Preeclampsia and/or Severe IUGR in 13 Women with Refractory Obstetric Antiphospholipid Syndrome (APS)  
Speaker: Eleftheria Lefkou (Greece)

Mixing Test Specific Cut-off is More Sensitive at Detecting in vitro Lupus Anticoagulant Inhibition than the Index of Circulating Anticoagulant with Multiple APTT and dRVVT Reagents  
Speaker: Osamu Kumano (Japan)

Evaluation of a New Formulation Dilute Russell’s Viper Venom Time for Detection of Lupus Anticoagulants  
Speaker: Gary Moore (United Kingdom)

Lupus Patients with IgM Antiphospholipid Antibodies Are at Risk of Thrombocytopenia and Haemolytic Anemia: Pooled Results from Five Systematic Reviews and Meta-Analyses  
Speaker: Stéphane Zuily (France)

Use of a Lupus Anticoagulant-Resistant Routine APTT Reagent as a Convenient Confirmatory Test  
Speaker: Osamu Kumano (Japan)

Antiphospholipid Antibodies in Children with Immune Thrombocytopenic Purpura  
Speaker: Umran Caliskan (Turkey)
IgG/IgM Antiphospholipid Antibodies Present in the Classification Criteria of the Antiphospholipid Syndrome: A Critical Review of Their Association with Thrombosis
Speaker: Hilde Kelchtermans (Netherlands)

Detection of Anti-Domain I Beta-2 Glycoprotein I Antibodies by Chemiluminescence Immunoassay in Antiphospholipid Syndrome Diagnosis
Speaker: Ludek Slavik (Czech Republic)

Study of Anti-Cardiolipin (IgG/IgM aCL) and Anti-Beta2-Glycoprotein I (anti-β2GPI) Antibodies in Patients with Ischemic Stroke (Ouest of Algeria)
Speaker: Katia Allal Taouli (Algeria)

Bone Marrow Necrosis and Pulmonary Thrombosis Associated with Antiphospholipid Syndrome
Speaker: Huseyin Tokgoz (Turkey)

Factor XIII Levels in Children with Extensive Venous Malformations and Chronic Disseminated Intravascular Coagulation: A Single Tertiary Centre Experience
Speaker: Saket Badle (United Kingdom)

Characterization of Laboratory Coagulation Parameters and Risk Factors for Intraventricular Hemorrhage (IVH) in Extremely Premature Neonates
Speaker: Jonathan Roberts (United States)

Increased Incidence and High Recurrence Rate of Venous Thromboembolism in Pediatric Oncology Patients in One Single Center over 25 Years
Speaker: Irene Klaassen (Netherlands)

Central Venous Catheters and Pediatric Thromboembolism, a Report from the Children’s Hospital Acquired Thrombosis (CHAT) Registry
Speaker: Julie Jaffray (United States)

Six Weeks Versus Three Months of Anticoagulant Treatment for Paediatric Central Venous Catheter-Related Venous Thromboembolism
Speaker: Fiona Newall (Australia)

Circumcision in Children with Haemophilia
Speaker: Hande Kızılocak (Turkey)

Pharmacokinetics and Pharmacodynamics of Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children, 2-12 Years Old, with Venous Thromboembolism
Speaker: Jacqueline M L Halton (Canada)

The Incidence of Thrombosis and PTS in Children Two Years after Central Venous Catheter Placement
Speaker: Fiona Newall (Australia)

Body Mass Index is Associated with Symptomatic Venous Thrombotic Events in Pediatric Oncology Patients: A Study from Maritimes, Canada
Speaker: Ketan Kulkarni (Canada)

Catheter-Related Arterial Thrombosis in Children: A Systematic Review
Speaker: Mattia Rizzi (Switzerland)

Diagnostic Challenges and Clinical Implications in Children with Congenital Bleeding Disorders: A Developing Country Perspective
Speaker: Sehar Khaliq (Pakistan)
Risk Factors for Hospital-Associated Venous Thromboembolism in Critically-Ill Children with Cardiac Disease Undergoing Cardiothoracic Surgery or Cardiac Catheter-Based Therapeutic Intervention  
Speaker: Brian Branchford (United States)

Risk Factor Assignment Concordance and Clinical Care Guideline Compliance for Prevention of Pediatric Hospital Acquired-Venous Thromboembolism  
Speaker: Brian Branchford (United States)

Paediatric Exposure to Intravenous Unfractionated Heparin  
Speaker: Fiona Newall (Australia)

Risk Factors Associated with Paediatric Thrombosis: A Five Years Retrospective Analysis in a Tertiary Care Hospital  
Speaker: Anila Rashid (Pakistan)

Endovascular Stents in Children  
Speaker: Gabriela Sciuccati (Argentina)

Pediatric Venous Thromboembolism: A Single Centre Experience  
Speaker: Nihal Özdemir (Turkey)

Prevalence and Characteristics of Epistaxis in Saudi Adolescents  
Speaker: Osamah Khojah (Saudi Arabia)

Frequency of Factor V Leiden and Prothrombin Mutation in Thrombotic Events in Children in North Moravian Region  
Speaker: Tomas Kuhn (Czech Republic)

HIF-2α Downregulates Tissue Factor Pathway inhibitor Expression in Breast Cancer  
Speaker: Xue Yan Cui (Norway)

Antithrombin Resistance Caused by c.1787G>A Mutation in Prothrombin Gene: Rare but Strong Inherited Thrombophilia  
Speaker: Predrag Miljic (Serbia)

TFPI Levels and Correlation with Coagulation Parameters Based on Longitudinal Observations in Healthy Subjects  
Speaker: Jadranka Koehn (Austria)

Diagnostic Issues in Antithrombin, Protein C and Protein S Deficiency in the Hungarian Population: Experience of a Large Thrombosis Laboratory  
Speaker: Zsuzsanna Bereczky (Hungary)

The Performance of Thrombin Generation Assays is Compromised at Reduced Plasma Levels of Antithrombin III  
Speaker: Michael Dockal (Austria)

Latex-Based Antithrombin Antigen Assays Can Give Falsely Reduced Levels  
Speaker: Peter Cooper (United Kingdom)

Estimates of within-Subject Biological Variation (CVI) of Antithrombin, Protein C, Protein S Free and Activity, and Activated Protein C Resistance (APCR) during Pregnancy  
Speaker: Ann Helen Kristoffersen (Norway)

Occurrence of Inherited Prothrombotic Factors, with Special Reference to Genetic Alterations in Antithrombin III, in North-Indian Patients with Recurrent Pregnancy Loss  
Speaker: Renu Saxena (India)
**Associations of Elevated FVIII Levels and APLAs with APCR-FV Leiden Patients with Deep Vein Thrombosis**  
Speaker: Amit Sharma (India)

**Identification and Significance of Anti-Mpl Autoantibody in Immune Thrombocytopenia**  
Speaker: XIAOLIN Zhang (China)

**Decreased miR-142-3p Promotes Survival of Hyperreactive B Cells by Targeting BAFF Receptor in Immune Thrombocytopenia**  
Speaker: Yang He (China)

**The Outcome of Eltrombopag Therapy in Immune Thrombocytopenia: A Multicenter Study from Turkey**  
Speaker: Gulsum Emel Pamuk (Turkey)

**Platelet Proteomics Profiling in Transfusion Adverse Events**  
Speaker: Chaker Aloui (France)

**Sensitive and Specific Functional Flow Cytometry Assay for the Rapid Diagnosis of Heparin-induced Thrombocytopenia and Thrombosis (HIT)**  
Speaker: Aaron Tomer (Israel)

**Comparison Head-to Head of Two Functional Assays in the Assessment of Heparin-Induced Thrombocytopenia**  
Speaker: Nadine Ajzenberg (France)

**Improved Regulatory B-Cell in Adult Patients with Chronic Immune Thrombocytopenia Treated with Rapamycin**  
Speaker: Lan Dai (China)

**Slow Responders to Helicobacter pylori Eradication in Adult Japanese Patients with Immune Thrombocytopenia**  
Speaker: Koji Miyazaki (Japan)

**mTOR Staining in Bone Marrow and Spleen Tissues of Immune Thrombocytopenia Patients is Associated with Shorter Relapse-Free Survival**  
Speaker: Gulsum Emel Pamuk (Turkey)

**Integrin Variations: Molecular Dynamics and Allostery**  
Speaker: Vincent Jallu (France)

**Can Heparin-Induced Multiple Electrode Aggregometry Improve Heparin-Induced-Thrombocytopenia (HIT) Diagnosis in the Intensive Care Unit Setting? A Prospective Study**  
Speaker: Vasiliki Gkalea (France)

**Very Low Incidence of Heparin-Induced Thrombocytopenia in Pediatric Patients, Even in those with a High Pretest Probability**  
Speaker: Takuma Maeda (Japan)

**A Rapid IgG Specific Lateral Flow Immunoassay Demonstrates Superior Diagnostic Performance to Platelet Factor 4/Heparin-Particle Gel Immunoassay in Screening for Heparin-Induced Thrombocytopenia**  
Speaker: Noppacharn Uaprasert (Thailand)

**The High Frequency of Antibodies against the Platelet Factor 4/Heparin Complex in Patients with Lung Transplantation is Not Associated with Thrombotic Events**  
Speaker: Mariette Adam (France)
Clinical Significance of Low CD4+/CD8+ Ratio in Patients with Immune Thrombocytopenic Purpura: A Single Centre Study
Speaker: Samina Naz Mukry (Pakistan)

An Activating Mutation of DIAPH1 Encoding Rho-Effector Diaphanous-Related Formin-1 Causes Inherited Macrothrombocytopenia Associated with Sensorineural Hearing Loss in a French Family
Speaker: Paquita Nurden (France)

Increased Platelet Expression in HIV Positive Treatment Naive Patients Does Not Correlate with CD4 Count
Speaker: Rael Onjula (Kenya)

Outward Migration of Procoagulant Platelets to Thrombus Surface is Driven by Thrombus Contraction and Decreased Adhesivity
Speaker: Dmitry Nechipurenko (Russian Federation)

Defects in TRPM7 Channel Function Deregulate Thrombopoiesis through Altered Cellular Mg2+ Homeostasis and Cytoskeletal Architecture
Speaker: Simon Stritt (Germany)

Clinical and Pathogenetic Characterization of ETV6-Related Thrombocytopenia (ETV6-RT), an Inherited Thrombocytopenia (IT) Predisposing to Childhood Acute Lymphoblastic Leukemia (ALL)
Speaker: Patrizia Noris (Italy)

PDK1 Determines Collagen-Dependent Platelet Activation and is Critical to Development of Ischemic Stroke in vivo
Speaker: Oliver Borst (Germany)

Three-Dimensional Electron Microscopy Reveals New Details for Platelet Granule Exocytosis: Granule-to-Granule Versus Granule-to-Platelet Membrane Fusion
Speaker: Anita Eckly (France)

Blood Coagulation Factors Bound to Procoagulant Platelets Are Concentrated in Their Cap Structures to Promote Clotting
Speaker: Nadezhda Podoplelova (Russian Federation)

Heat Shock Protein 70 (Hsp70) Regulates Platelet Integrin Activation, Granule Secretion and Aggregation
Speaker: Rachel A. Rigg (United States)

Severe Aortic Stenosis-Induced Platelet Activation and High Plasma Lipoxygenase Products Are Rapidly Corrected by Transcatheter Aortic Valve Replacement
Speaker: Marie Levade (France)

Risk Factors for Clopidogrel High on-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy
Speaker: Dragana Backovic (Serbia)

Defining the Mac-1 I-domain Binding Site of the GPIIbα N-terminal Domain
Speaker: Juliet Morgan (United Kingdom)

Platelets Are dispensable for Antibody-Mediated Transfusion-Related Acute Lung Injury in the Mouse
Speaker: Beatrice Hechler (France)
Scientific Schedule & Program

Procoagulant Platelets and the Role of Mitochondria in Their Formation  
Speaker: Sergei Obydennyi (Russian Federation)

Myr-RK6 Peptide Selectively Regulates Outside-in Signaling Transduction-Related Functions in Human Platelets  
Speaker: Zhangbiao Long (China)

Regulation of αIIbβ3 Signalling by the ITIM-Containing Receptor G6b-B  
Speaker: Yotis Senis (United Kingdom)

ABO(H) Blood Group Expression Modifies Platelet Function  
Speaker: Eimear Dunne (Ireland)

Fibrin Fibers from Cardiovascular Disease Patients on Aspirin Are More Extensible than Fibers from Healthy Individuals  
Speaker: Martin Guthold (United States)

The Impact of CYP2C19 *2, *3, CYP4F2 *3, Fibrinogen β (C-148T) Genotype and Clinical Factors on Antiplatelet Effect during Induction of Ticagrelor and Aspirin Therapy  
Speaker: Vacis Tatarunas (Lithuania)

Development and Upscaling of the Purification Process of Snake Venom Antiplatelet Agents  
Speaker: Bat-Erdene Jugder (Mongolia)

Real Time Dose Adjustment Utilizing Point of Care Platelet Reactivity Testing in a Double Blind Study of Prasugrel in Children with Sickle Cell Anemia (SCA)  
Speaker: Joseph A. Jakubowski (United States)

Measurement of Platelet Serotonin Secretion by HPLC-Electrochemical Detection (ED) in a Clinical Hemostasis Laboratory: Sensitive, Specific and Accurate Assay for Diagnosing Platelet Secretion Defects and Heparin-Induced Thrombocytopenia  
Speaker: Diego Mezzano (Chile)

Assessment of Platelet Function on the Routine Coagulation Analyzer Sysmex CS-2000i  
Speaker: Katsushi Kobayashi (France)

Platelet Calcium Flux Measurement by Flow Cytometry in Diluted Whole Blood  
Speaker: Barry Wilbourn (United Kingdom)

Role of Platelets in the Spatial Clot Growth Investigated with Reaction-Diffusion in vitro Experimental Mode  
Speaker: Anna Balandina (Russian Federation)

Psoralen and Ultraviolet A Light Treatment Inhibits Activation of PI3K Dependent Effector Kinases by Disturbing Cell Membrane Packing  
Speaker: Hendrik Feys (Belgium)

Why Platelets Have Two PARs?  
Speaker: Mikhail Panteleev (Russian Federation)

Role of Formyl Peptide Receptors in the Regulation of Thrombosis and Haemostasis  
Speaker: Maryam Salamah (United Kingdom)

Functional and Molecular Characterization of an Inherited Abnormal Platelet Function Related to a New CalDAG-GEFI Protein Variant in an Argentinean family  
Speaker: Emilse Bermejo (Argentina)
Science Schedule & Program

Thiol Isomerase Denitrosylase Activity in Platelet Activation
Speaker: Roelof Bekendam (United States)

Value of Whole Blood Impedance Aggregometry in the Diagnosis of Inherited Platelet Function Disorders
Speaker: Valerie Proulle (France)

Diagnostic value of a Flow Cytometry Based Platelet Function Test Compared with Light Transmission Aggregometry in Patients with Unknown Bleeding Disorders
Speaker: Ivar van Asten (Netherlands)

Antiplatelet Aggregation Activity of Two Schiff Base Ligands Derived from 3-Hydroxy-2-Naphthaldehyde and Their Corresponding Copper(II) Complexes
Speaker: Aurora de la Peña Diaz (Mexico)

TPO agonist for the Treatment of May Hegglin Anomaly Deriving from MYH9 Mutation
Speaker: Hanane Bezzou (Algeria)

In vitro Antiplatelet Activity of Anthocyanin
Speaker: Almottesembellah Gaiz (Australia)

Sticky Platelet Syndrome - Questionable or Independent Risk Factor for Thrombosis?
Speaker: Jan Stasko (Slovakia)

An Atypical IgM Antibody that Induces Integrin αIIβ3 Activation and Glanzmann Thrombasthenia-Like Phenotype Associated with Macrothrombocytopenia
Speaker: Chloé James (France)

Membrane Microvesicles Generated in Stored Blood Components
Speaker: Emmanuel Rafael Hernandez-Garzon (Mexico)

Atabrine Binds to the Platelet 5HT2A Receptor and is Not Taken up into Platelet Dense Granules
Speaker: Elaine Uhr (Australia)

Aspirin Response in Myeloproliferative Patients using Multiplate Aggregometry
Speaker: Pavol Chudakou (United Kingdom)

Influence of Exercise Intensity on Platelet Aggregation in Patients with Heart Disease Patients
Speaker: Hitoshi Adachi (Japan)

Platelet Function Disorders Diagnosis Using Flow Cytometry in Algeria: About 19 Families
Speaker: Houda Boukerb (Algeria)

Predictors of the Secondary Aspirin Resistance in Patients with Coronary Artery Disease over 60 (according to the 10-year follow-up)
Speaker: Viktoriia Zharinova (Ukraine)

Poster Session and Networking

Poster Session
19:00 - 21:00
Antigone 2
Transient Impact of Treatment Exposures and One-year Incidence of Thrombosis in Multiple Myeloma: A Case-time-Control Analysis
Speaker: Joshua Brown (United States)

Acute Isolated Superficial-Vein Thrombosis is Associated with Substantial Comorbidity and History of Venous Thromboembolic Complications
Speaker: Marie-Antoinette Sevestre (France)

Development of a New Risk Assessment Model for VTE Specific for Ambulatory Patients with Lung Adenocarcinoma on Chemotherapy. The ROADMAP Study
Speaker: Grigoris T Gerotziafas (France)

Prevalence of Hemostatic Defects in Dengue Hemorrhagic Fever in a Tertiary Care Hospital in Karachi
Speaker: Arshi Naz (Pakistan)

Validation of the ISTH-SSC Bleeding Assessment Tool for the Diagnosis of Inherited Bleeding Disorders: Experience from a Tertiary Care Center in South India
Speaker: Pagadalu Lokababu Ambika (India)

Sub-Segmental Pulmonary Embolism – Understanding the Clinical Significance
Speaker: Melanie Ferreira (Portugal)

Retrievable Inferior Vena Cava Filters Use in Elderly Patients
Speaker: Amihai Rottenstreich (Israel)

Air Pollution and Venous Thrombosis: A Meta-Analysis
Speaker: Qing-Yun Wang (China)

Acute Venous Thromboembolism in Clinical Practice - Baseline Bleeding Risk Results from the European PREFER in VTE Registry
Speaker: Alexander Thomas Cohen (United Kingdom)

Ten Years of Cerebral Venous Thrombosis (CVT) in Northeast Melbourne, Australia: Male Gender and Presence of Myeloproliferative Neoplasm is Associated with Thrombotic Recurrence in Unprovoked Events
Speaker: Prahlad Ho (Australia)

Performance of the STA®-Liatest® D-DI Plus for the Exclusion of Pulmonary Embolism in Emergency Departments using an Age-Adjusted Cut-Off
Speaker: Anne-Marie Fischer (France)

D-Dimer Assay Methods State-of-the Art from External Quality Assessment Results
Speaker: Chantal Bon (France)

Impact of Severe ADAMTS-13 Deficiency in Patients with Thrombotic Thrombocytopenic Purpura (TTP) on Recurrences
Speaker: Laura Russo (Italy)

Description of a New Prothrombin Gene Variant C20214T
Speaker: Didier Jambou (France)

Venous Thromboembolism and Variants of FGG, F11 and AB0 in Czech Republic
Speaker: Jan Kvasnicka (Czech Republic)

High Sensitive LOCI Based F 1+2 Immunoassay for Quantification of Prothrombin Fragment 1+2 in Human Plasma Samples on the New INNOVANCE BCS LT System
Speaker: Matthias Ehm (Germany)
Getting the Right Product to the Right Patient - Proposed Platelet Concentrate Screening to Improve Transfusion Outcome  
Speaker: Elisabeth Mauer-Spurej (Canada)

Evaluation of the Risk Factors of Recurrence of Cerebral Venous Thrombosis  
Speaker: Suely Rezende (Brazil)

Does Thrombin Generation Test Predict the Outcome of Ischemic Stroke after Thrombolysis Treatment?  
Speaker: Zsuzsa Bagoly (Hungary)

An Automated Indicator for Interfering Substances in Hemostasis  
Speaker: Silke Echternacht (Germany)

Establishing Reference Intervals for Technothrombin®TGA Based on Plasma Samples from Healthy Blood Donors  
Speaker: Lieselotte Wagner (Austria)

Sudden Onset Vision Loss as an Initial Manifestation of Elevated Serum Lipoprotein(a) Levels  
Speaker: Huseyin Tokgoz (Turkey)

Concerns on Reliability of Haemostasis Activation Markers in a Cohort of Healthy Volunteers  
Speaker: Eric Mercier (France)

Concerns on Reliability of Haemostasis Activation Markers in Patients with a History of Venous Thromboembolism  
Speaker: Eric Mercier (France)

Mean Platelet Volume as a Biomarker of Disease Activity in Polymyalgia Rheumatica  
Speaker: Gulsum Emel Pamuk (Turkey)

Thrombocytopenia and Altered Coagulation as Independent Predictors of the Etiology of Acute Undifferentiated Febrile Illness (AUFI) in Adults Presenting to Emergency in a Tertiary Care Hospital in North India  
Speaker: Ashish Bhalla (India)

Red Cell Distribution Width is Associated with Atherosclerotic Cardiovascular Mortality in Gouty Arthritis  
Speaker: Gulsum Emel Pamuk (Turkey)

Biomarkers of Hypercoagulability and Clinical Variable Related with VTE Risk in Ambulatory Patients with Lung Adenocarcinoma on Chemotherapy. The ROADMAP Study  
Speaker: Grigoris T Gerotziafas (France)

Increased Mortality Associated with Omission of Venous Thrombo-embolism (VTE) Prophylaxis in a Rural Intensive Care Unit in Victoria, Australia  
Speaker: Henry Yao (Australia)

Thromboelastography and Thrombin Generation Test Follow-Up in Patients Developing Sepsis or Systemic Inflammatory Response Syndrome  
Speaker: Leyla Calmette (France)

False Negative and False Positive Responses in Ristocetin-Induced Platelet Aggregation Mixing Studies  
Speaker: Juan Pablo Frontroth (Argentina)
Thrombus Formation and Platelet Dynamics Visualization by Multi-scale in vivo 1P, 2P Microscope, and On-chip Imager  
Speaker: Satoshi Nishimura (Japan)

Control of Protein Disulfide Isomerase by Nitric Oxide  
Speaker: Roelof Bekendam (United States)

CD146 Deficiency Leads to Accelerated Atherosclerosis in Mice through Upregulation of RANTES  
Speaker: Marie Nollet (France)

SGK1 Deficiency Protects from Neointima Formation via Reduction of Ca2+-Dependent VSMC Migration  
Speaker: Sascha Geue (Germany)

Lysine-Rich Histones Induce Weibel-Palade Body Exocytosis through a Calcium, Caspase and Charge-Dependent Mechanism  
Speaker: Alison Michels (Canada)

Significant miRNA Alterations in Human Endothelial Cells as a Result of Staphylococcus aureus Infection  
Speaker: Rebecca L Watkin (Ireland)

Gain-of-Function Mutation in TRPV4 Identified in Patients with Osteonecrosis of the Femoral Head  
Speaker: Chantal Séguin (Canada)

Endothelial Cells Are Important Players in the Pathogenesis of Thrombosis in Myeloproliferative Neoplasms  
Speaker: Chloé James (France)

Soluble CD146 Priming Boosts Survival and Regenerative Properties of Endothelial Colony-Forming Cells  
Speaker: Marie Nollet (France)

Activated Protein C (APC) Down Regulates Neutrophil Extracellular Traps (NETs): Potential Contributing Mechanism for Anti-Inflammatory and Antithrombotic Effects Of APC  
Speaker: Laura D Healy (United States)

Platelet-derived Factor V Is an Important Determinant of Ischemia-mediated Angiogenesis in a Mouse Hindlimb Model  
Speaker: Jianbo Wu (China)

What is the best animal model to specifically target endothelial cells, without concomitant involvement of the hematopoietic lineage?  
Speaker: Chloé James (France)

Gaining Insight into the Early Signals Generated in Human Endothelial Cells as a Result of Bacterial Infection  
Speaker: Tony McHale (Ireland)

Development of a Platform to Quantify the Colocalization of Neutrophil Extracellular DNA and Coagulation Factors using Immunofluorescence-Based Microscopy  
Speaker: Tiffany Chu (United States)

Platelet Function and Microparticles Levels for Patients with Paroxysmal and Persistent Atrial Fibrillation Including during Acute Episodes  
Speaker: Line Pourtau (France)
Biological Reference Materials to Standardize Measurements of Extracellular Vesicles
Speaker: Pia Siljander (Finland)

SIRT1 Deficiency in Endothelial Progenitor Cells Drives Pro-Senescent Microparticles Release through MKK6 Upregulation
Speaker: Anne-Line Chateau (France)

Natural Killer Cells Are Potent Effectors of Thromboinflammatory Endothelial Dysfunction Associated with Antibody-mediated Transplant Vasculopathy
Speaker: Philippe Poncelet (France)

Microparticles from Acute Promyelocytic Leukemia Generate Plasmin in a Urokinase-Dependent Manner
Speaker: Coralie Judicone (France)

Circulating Lipoprotein (a) Increases Aortic-Valve Calcification
Speaker: José Roberto Garrido Argueta (Mexico)

Association of Nitric Oxide Synthase3 (NOS3) Gene Polymorphisms with Acute Myocardial Infarction in Indian Patients
Speaker: Sunil Kumar (India)

Endothelial Cells Response to Staphylococcus Aureus: Critical Role of Clumping Factor A in Sepsis
Speaker: Carolina Denis Garciarena (Ireland)

Acidic Preconditioning Improves Endothelial Progenitor Cell Survival and Functionality under Inflammatory Conditions
Speaker: Hebe Agustina Mena (Argentina)

Recanalization Rates in Patients with Proximal Deep Venous Thrombosis Patients – A Prospective Observational Study from a Tertiary Care Hospital in North India
Speaker: Pankaj Malhotra (India)

Application of a Clot Based Assay to Measure the Procoagulant Activity of Stored Allogeneic Red Blood Cell Concentrates
Speaker: Francois Mullier (Belgium)

Blood Outgrowth Endothelial Cells from Type 3 von Willebrand Disease Patients Display Abnormal Angiogenesis
Speaker: Soundarya Nivedita Selvam (Canada)

Inhibition of vWF Secretion with Novel Galpha 12 N-terminal alpha-SNAP Binding Domain Peptide Increases Survival in Septic Mice
Speaker: Luiza Rusu (United States)

Role of the Arterial Pulsatility in the Modulation of von Willebrand Factor Multimerisation in an Animal Model of Continuous-Flow Left Ventricular Assist Support
Speaker: Antoine Rauch (France)

Possible Role of Protein Disulfide Isomerase PDIA in Mechanisms of von Willebrand Disease Type 3
Speaker: Maria Alexandra Brehm (Germany)

Structure and Mechanics of von Willebrand factor Are Regulated by pH-Dependent Interactions in Dimeric Subunits
Speaker: Jochen P. Müller (Germany)
Scientific Schedule & Program

Childhood-Onset Acquired Thrombotic Thrombocytopenic Purpura: The French Reference Center for Thrombotic Microangiopathies Experience  
Speaker: Bérangère Joly (France)

Clinical-Biological-Genetic Features of Adulthood-Onset Thrombotic Microangiopathy with Severe ADAMTS13 Deficiency: The French Experience  
Speaker: Agnès Veyradier (France)

Platelet-Independent Binding of Activated Erythrocytes to von Willebrand Factor: A Pro-Active Role for Erythrocytes in Primary Hemostasis  
Speaker: Michel Smeets (Netherlands)

Platelet type von Willebrand Disease (PT-VWD) Posing Diagnostic and Therapeutic Challenges - Small Case Series  
Speaker: Maha Othman (Canada)

Divergent Clinical and Laboratory Features of Acquired VWF Abnormalities in Patients with Pulmonary Hypertension versus High Shear Cardiac Lesions: Importance of the Procoagulant Property of VWF Multimers  
Speaker: Joseph Blackshear (United States)

Severe Acquired von Willebrand Syndrome - A Single Centre Experience  
Speaker: Ingrid Hrachovinova (Czech Republic)

Speaker: Imre Bodó (Hungary)

Functional Characterization of c.4876instgc and c2555a>g VWF Gene Variants Identified Type 2 VWD Patient Population in Turkey  
Speaker: Ergul Berber (Turkey)

Inhibition of a Mouse-Human Chimeric Monoclonal Antibody to von Willebrand Factor on VWF A3-Collagen and VWF A1-Platelet Interactions  
Speaker: Yiming Zhao (China)

Monoclonal Antibody that Binds to the C-Terminus of the A2 Domain of von Willebrand Factor Effectively Inhibits Platelet Adhesion to Collagen in a Force-Dependent Manner  
Speaker: Miguel Cruz (United States)

Immunohistochemical Analysis of von Willebrand Factor Biodistribution in Liver Endothelial Cells  
Speaker: Laura L Swystun (Canada)

Modification of ADAMTS13 Isoforms by Estradiol and Histamine Treatment  
Speaker: Célia Dos Santos (Argentina)

Speaker: Chloé James (France)

Impact of Platelet Reactivity on Individual Thrombin Generation in Type 3 and 2 von Willebrand Disease: Results from a Small Prospective Study  
Speaker: Timea Szanto (Finland)
### Scientific Schedule & Program

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Evaluation of a New Collagen-Like Protein with von Willebrand Factor Binding Activity: toward a New VWF: CBA</td>
<td>Emmanuel De Maistre (France)</td>
</tr>
<tr>
<td>Recombinant von Willebrand Factor Kinetics and Ultralarge Multimer Content in Severe von Willebrand Disease Patients</td>
<td>Bruce Ewenstein (United States)</td>
</tr>
<tr>
<td>Phenotype Analysis Associated to p.Arg1315Cys (p.R1315C); the Value of DDAVP and VWFpp/VWF: Ag Ratio to Reach the Diagnosis</td>
<td>Alicia N. Blanco (Argentina)</td>
</tr>
<tr>
<td>A Comparative Evaluation of a New Fully-Automated Assay for von Willebrand Factor Collagen Binding Activity to an Established Method</td>
<td>Francesca Stufano (Italy)</td>
</tr>
<tr>
<td>Von Willebrand Factor (VWF) Assays and the Diagnosis of von Willebrand Disease (VWD). Who Follows the Guidelines?</td>
<td>Ian Jennings (United Kingdom)</td>
</tr>
<tr>
<td>Computer Modeling of Platelet Adhesion to a Surface with Grafted von Willebrand Factor Multimers</td>
<td>Aleksey Belyaev (Russian Federation)</td>
</tr>
<tr>
<td>Effects of bilirubin on ADAMTS-13 Activity Measured with a FRETS rVWF73 Substrate-Based Fluorescent Assay</td>
<td>Arnaud Bonnefoy (Canada)</td>
</tr>
<tr>
<td>Calibration with the 1st International Standard for ADAMTS-13 Using Technozym® ADAMTS-13 Activity Assay: Patient Correlation Data</td>
<td>Nikolaus B. Binder (Austria)</td>
</tr>
<tr>
<td>Ferritin Promotes Secretion of von Willebrand Factor (VWF) from Endothelial Cells: a Potential Mechanistic Implication for Patients with Pathological Immune Activation</td>
<td>Dalia Bashir (United States)</td>
</tr>
<tr>
<td>Understanding “Normal”: Baseline VWF Characteristics in Normal BOECs</td>
<td>Mackenzie Bowman (Canada)</td>
</tr>
<tr>
<td>ADAMTS13 in Chronic Liver Diseases: Data from the Developing World</td>
<td>Priyanka Saxena (India)</td>
</tr>
<tr>
<td>Bleeding Score in Type 1 von Willebrand [vWD] Patients using the ISTH-BAT Questionnaire</td>
<td>Anil Pathare (Oman)</td>
</tr>
<tr>
<td>Correlation of Phenotypic and Genotypic Expression of VWD Type I and II in Pakistani Patients</td>
<td>Shariq Ahmed (Pakistan)</td>
</tr>
<tr>
<td>Comparison between VWF:RCo and VWF:CB in a 2B VWD Cohort</td>
<td>Adriana Ines Woods (Argentina)</td>
</tr>
<tr>
<td>Phenotype of Congenital Factor XIII Deficiency in Women: Report of the French Cohort</td>
<td>Christophe Martinaud (France)</td>
</tr>
<tr>
<td>Abnormal Platelet GPIIbα and Pregnancy Outcome: An Exploratory Study</td>
<td>Maha Othman (Canada)</td>
</tr>
</tbody>
</table>
A Meta-Analysis of Low-Molecular-Weight Heparin to Prevent Pregnancy Loss in Women With Inherited Thrombophilia
Speaker: Leslie Skeith (Canada)

Prevention of Recurrent Pregnancy Complications in Patients with Thrombophilia
Speaker: Alexander Makatsariya (Russian Federation)

Hematologic Alterations in Patients Undergoing Controlled Ovarian Stimulation for in vitro Fertilization: A Prospective Observational Pilot Study
Speaker: Maria T. DeSancho (United States)

Sociodemographic Characteristics of Women with Postpartum Hemorrhage: A Nationwide Inpatient Sample (NIS)-Based Analysis
Speaker: Ariela Marshall (United States)

The Use of TEG/RoTEM in Pregnancy and Pregnancy Associated Complications: Results of a Worldwide Survey by the ISTH SSC for Women’s Health Issues In Thrombosis and Haemostasis
Speaker: Maha Othman (Canada)

Hyperfibrinolysis as One of the Reasons of Recurrent Fetal Loss in the Pregnant Women
Speaker: Vladimir Sukhanov (Russian Federation)

Risk Assessment of Venous Thromboembolism (VTE) and Thromboprophylaxis in Women Hospitalized with Multiple Pregnancy
Speaker: Venina Barros (Brazil)

Inherited Thrombophilia Influences Localization and Extent of Pregnancy Related Deep Venous Thrombosis
Speaker: Jelena Bodrozic (Serbia)

Intravenous Iron Therapy in Non-Anemic Iron-Deficient Menstruating Adolescent Females with Fatigue
Speaker: Ruchika Sharma (United States)

Thromboelastography in Pregnancy: Establishing Reference Ranges in Third Trimester and Exploring Predictive Value for Postpartum Haemorrhage
Speaker: Rezan Abdul-Kadir (United Kingdom)

Screening of Female Family Members of von Willebrand Disease Patients: Utility of a Screening Tool
Speaker: Claire Philipp (United States)

Coagulation Factor Changes during Pregnancy in Women with Inherited Bleeding Disorders
Speaker: Angela Pereira (United Kingdom)

Effect of Pregnancy on the Course of Immune Thrombocytopenia: A Retrospective Multicenter Study
Speaker: Gulsum Emel Pamuk (Turkey)

The Clinical Presentations and Management of Hermansky-Pudlak Syndrome in the Obstetric and Gynaecology Setting - A Systemic Review
Speaker: Deborah Obeng-Tuudah (United Kingdom)

Proposed Trial: HYPATIA - A Prospective Randomised Controlled Trial of Hydroxychloroquine versus Placebo during Pregnancy in Women with Antiphospholipid Antibodies
Speaker: Karen Schreiber (United Kingdom)
**Scientific Schedule & Program**

**First Venous Thromboembolic Episodes in Women with Antithrombin Deficiency often associated with Oral Contraceptives or Pregnancy**
Speaker: Ariela Marshall (United States)

**Evaluation of Protein C and Protein S Levels in Preeclamptic Women Seen in a Tertiary Institution in the Niger-Delta Region of Nigeria - Any Role in the Development of Preeclampsia?**
Speaker: Helen C. Okoye (Nigeria)

**High Factor VIII and Advanced Disease Are Associated with Risk of Recurrent Thrombosis in Women with Breast Cancer**
Speaker: Mirjana Kovac (Serbia)

**Multicenter Registry on Thrombophilia and Pregnancy Loss: The OTTILIA Study**
Speaker: Elvira Grandone (Italy)

**Management of Pregnancy in vWD Patients**
Speaker: Vera Geierova (Czech Republic)

**The Dependence of Low Molecular Weight Heparin Efficacy (Tested by Anti Xa) on the Level of Antithrombin - A Case Report of a Pregnant Patient with Antithrombin Deficiency**
Speaker: Jana Prochazkova (Czech Republic)

**Yes or No for Anticoagulant Thromboprophylaxis in Pregnant Women with Repeated Pregnancy Loss?**
Speaker: Lucia Stanciakova (Slovakia)

**The Role of LMWH to Improve the Pregnancy Outcome**
Speaker: Maria Hulikova (Slovakia)

**Antibodies to Factor XII and Heterozygous Factor V Leiden Thrombophilia: Are They Responsible of Intrauterine Fetal Death in a Case of Varicella Infection during Pregnancy?**
Speaker: Brahim Nciri (Tunisia)

**Absence of Pre-Operative VWF Workup is Associated with Increased Intraoperative Bleeding during Wilm’s Tumor Resection**
Speaker: Shiu-Ki Hui (United States)

**High Variation of Peri-Operative Bridging Use in Real-World Practice: Results from a Clinician Survey**
Speaker: Geoffrey Barnes (United States)
Scientific Schedule & Program

Thursday, 26. May 2016

Registration
07:00 - 18:30

Registration

Master Class Session
07:30 - 08:15

Rondelet

Master Class

Do We Need Laboratory Control for DOAC?
Speaker: Pierre Sié (France)

Master Class Session
07:30 - 08:15

Barthez

Master Class

Biochemistry of Coagulation
Speaker: Olivier Christophe (France)

Master Class Session
07:30 - 08:15

Sully 1

Master Class

Inhibitors in Hemophilia: How to Prevent Them
Speaker: Marijke van den Berg (Netherlands)

Master Class Session
07:30 - 08:15

Sully 2

Master Class

Diagnosis and Treatment of Antiphospholipid Syndrome
Speaker: Vittorio Pengo (Italy)
Scientific Schedule & Program

Plenary Session
08:30 - 10:00  

**Plenary Session**

Co-Chair: Sabine Eichinger (Austria)
Co-Chair: Jean-François Schved (France)

- **Welcome from Mayor of Montpellier**  
  Speaker: Philippe Saurel (France)  
  08:30
- **Welcome from Dean of Faculty at CHU Montpellier**  
  Speaker: Jacques Bringer (France)  
  08:35
- **The Future of Gene Therapy**  
  Speaker: Alain Fischer (France)  
  08:40
- **Publishing Matters, a Pas de Deux**  
  Speaker: Frits Rosendaal (Netherlands)  
  09:20

Exhibition
09:45 - 17:00  

**Exhibition**

Plenary Session
10:30 - 12:00  

**Plenary Session**

Co-Chair: Jean-François Schved (France)
Co-Chair: Sabine Eichinger (Austria)

- **Regulation of Fibrin Clot Structure and Implications for Thrombosis**  
  Speaker: Robert Ariëns (United Kingdom)  
  10:30
- **New Treatments in Hemophilia**  
  Speaker: Michael Makris (United Kingdom)  
  11:00
- **Von Willebrand Factor: A Marker of Blood Flow in Cardiovascular Diseases**  
  Speaker: Sophie Susen (France)  
  11:30

Corporate Symposium
12:45 - 14:00  

**Corporate Symposium-CS04**

For additional information, please [click here](#)

Novo Nordisk: The Chromogenic Assay: Considerations for the Monitoring of Coagulation Factor Activity in Haemophilia
Scientific Schedule & Program

Welcome & introduction
Speaker: Claude Negrier (France) 12:45

A Computer-Based Model to Assess Costs Associated With the Use of One-Stage and Chromogenic Factor Activity Assays
Speaker: Guy Young (United States) 12:50

Implementation of Chromogenic Factor Activity Assays in Clinical Laboratory Practice
Speaker: Jens Müller (Germany) 13:05

Mechanistic Studies to Explain Inconsistencies in the Performance of Silica-Based aPTT Reagents
Speaker: Steffen Rosén (Sweden) 13:20

Results From a Multi-Centre Qualification of Selected One-Stage aPTT and Chromogenic Factor Activity Assays
Speaker: Stefan Tiefenbacher (United States) 13:35

Closing Remarks
Speaker: Claude Negrier (France) 13:55

Corporate Symposium
12:45 - 14:00 Einstein

Corporate Symposium-CS05
For additional information, please click here

Bayer Thrombosis: Patient Pathways in VTE Care
12:45
Opening and Introduction
Speaker: Ajay Kakkar (United Kingdom)

Adapting VTE Guidelines to Clinical Care
Speaker: Rodney Hughes (United Kingdom) 12:50

Managing Challenging Patients With VTE
Speaker: Jan Beyer-Westendorf (Germany) 13:05

Minimizing the Risk of Bleeding
Speaker: Jeffrey I. Weitz (Canada) 13:20

The Challenge of Cancer-Associated Thrombosis
Speaker: Ajay Kakkar (United Kingdom) 13:35

Questions and Answers
Speaker: Ajay Kakkar (United Kingdom) 13:50
Corporate Symposium
12:45 - 14:00

Corporate Symposium-CS06
For additional information, please click here

**LFB: For Inhibitor Patients: A New Recombinant FVIIa**

- **Welcome to Montpellier Introduction**
  Speaker: Michael Wang (United States)  
  12:45

- **New Insights on Inhibitors, the Alloantibodies to FVIII or FIX**
  Speaker: Sebastien Lacroix-Desmazes (France)  
  12:55

- **Binding of rhFVIIa (LR769) to Receptors Involved in Its Mechanism of Action**
  Speaker: Jerry Grandoni (United States)  
  13:10

- **Update on the Clinical Results of rhFVIIa (LR769) and Looking to the Future**
  Speaker: Jeffry Lawrence (United States)  
  13:25

- **rhFVIIa, From Expectations to Practice: US Experience Sharing**
  Speaker: Michael Wang (United States)  
  13:35

- **Questions & Answers**
  13:45

- **Closing Remarks**
  Speaker: Michael Wang (United States)  
  13:55

SSC Session
14:15 - 16:15

**Von Willebrand Factor, Part II**

- **Results From Large Population Studies of Von Willebrand Disease**
  **Moderator: James O'Donnell, Ireland**
  Moderator: James O'Donnell (Ireland)  
  14:15

- **Results From the WIN Study**
  Speaker: Frank Leebeek (Netherlands)  
  14:30

- **Results From the Canadian Study**
  Speaker: Paula James (Canada)  
  14:45

- **The Zimmerman Project**
  Speaker: Robert Montgomery (United States)  
  15:00

- **The PCM-EVW-ES Experience**
  Speaker: Javier Batlle (Spain)  
  15:15

- **Low VWF vs. VWD Type 1: Optimizing the Definition of VWD Type 1**
  Moderator: Alberto Tosetto (Italy)  
  15:30

- **VWD Type 1 or Low Von Willebrand Factor?**
  Speaker: David Lillicrap (Canada)  
  15:45
## Scientific Schedule & Program

### Mutational Spectrum in VWD type 1
Speaker: Anne Goodeve (United Kingdom)

### Domain Distribution of Type 1 VWD Sequence Variants
Speaker: Pam Christopherson (United States)

### Discussion, Moderator: Alberto Tosetto, Italy
Moderator: Alberto Tosetto (Italy)

### Platelet Physiology

#### Featured Abstract Presentation: Defects in TRPM7 Channel Function Deregulate Thrombopoiesis Through Altered Cellular Mg2+ Homeostasis and Cytoskeletal Architecture
Speaker: Simon Stritt (Germany)

#### Business Session, Moderators: Paolo Gresele, Italy and Martine Jandrot-Perrus, France
Moderator: Paolo Gresele (Italy)
Moderator: Martine Jandrot-Perrus (France)

#### Overview of Platelet Physiology SSC and Project Updates
Speaker: Paolo Gresele (Italy)

#### Consensus on the Methods for the Study of Platelet Secretion
Speaker: Diego Mezzano (Chile)

#### Guidance on the Measurement of Platelet Dimensions: Methods and Clinical Use
Speaker: Patrizia Noris (Italy)

#### Generation of Guidance on the Use of Platelets in Regenerative Medicine
Speaker: Paul Harrison (United Kingdom)

#### Laboratory Monitoring of P2Y12 Inhibitors: A Position Statement
Speaker: Andrew Frelinger (United States)

#### Evaluation of the Bleeding Assessment Tool (BAT) for the Assessment of Inherited Platelet Function Disorders: Final Results
Speaker: Paolo Gresele (Italy)
Speaker: Paul Harrison (United Kingdom)

### Hemostasis and Malignancy

#### Featured Abstract Presentation: Transient Impact of Treatment Exposures and One-Year Incidence of Thrombosis in Multiple Myeloma: A Case-Time-Control Analysis
Speaker: Joshua Brown (United States)
Scientific Schedule & Program

Prediction and Prevention of Cancer-Associated Thrombosis

Biomarkers for the Prediction of Venous Thromboembolism in Cancer Patients
Speaker: Anna Falanga (Italy)

Primary Prevention of Venous Thromboembolism in Cancer Patients

Debate: Pros and Cons of Occult Cancers Screening in Patients With Venous Thromboembolism

Pro Occult Cancer Screening in Patients With Venous Thromboembolism Presentation Start Time
Speaker: Gregoire Le Gal (Canada)

Contra Occult Cancer Screening in Patients With Venous Thromboembolism
Speaker: Marc Carrier (Canada)

Rebuttal and Questions
Speaker: Gregoire Le Gal (Canada)
Speaker: Marc Carrier (Canada)

SSC Session
14:15 - 16:15 Antigone 3

Plasma Coagulation Inhibitors

Welcome, Goals & Introductions
Speaker: Richard Marlar (United States)

Update on Ongoing Projects, Moderator: Jun Teruya, United States
Moderator: Jun Teruya (United States)

Protein S Activity Assays
Speaker: Ian Jennings (United Kingdom)

Racial Differences in Plasma Coagulation Inhibitors
Speaker: Hiroko Tsuda (Japan)

Update & Progress of Clinical Testing of Plasma Coagulation Inhibitors, Moderator: Ian Jennings, United Kingdom
Moderator: Ian Jennings (United Kingdom)

Introduction
Speaker: Richard Marlar (United States)

Antithrombin
Speaker: Piet Meijer (Netherlands)

Protein C
Speaker: Peter Cooper (United Kingdom)

Protein S
Speaker: Richard Marlar (United States)
**APC- Resistance**  
Speaker: Gary Moore (United Kingdom)

---

**Predictive and Diagnostic Variables in Thrombotic Disease**

**Introduction**  
Speaker: Suzanne Cannegieter (Netherlands)

**Featured Abstract Presentation: Prothrombin Conversion and Thrombin Inactivation in Patients Anticoagulated With Enoxaparin, Vitamin K Antagonists, and Rivaroxaban**  
Speaker: Romy Kremers (Netherlands)

**Diagnosis of VTE, Moderators: Gregoire le Gal, France and Marc Righini, Switzerland**

- Moderator: Marc Righini (Switzerland)
- Moderator: Gregoire Le Gal (Canada)

**Novel Nuclear Medicine Imaging Techniques for Diagnosing PE**  
Speaker: Gregoire Le Gal (Canada)

**Modern Diagnosis of CTEPH**  
Speaker: Frédéric Lador (Switzerland)

**MRI for Diagnosing Acute and Recurrent DVT**  
Speaker: Menno Huisman (Netherlands)

**Ongoing Studies (PEGeD, 4D, THEIA, YEARS in Pregnancy, VALID, VISTA, IPD Studies for DVT and PE Diagnosis)**  
Speaker: Sabine Eichinger (Austria)  
Speaker: Clive Kearon (Canada)  
Speaker: Menno Huisman (Netherlands)  
Speaker: Geert-Jan Geersing (Netherlands)

---

**Joint session: Biorheology and VWF**

**VWF Function Under Pathological Flow Conditions in Vivo and in Extracorporeal Devices, Moderators: Keith Neeves, United States and Jorge Di Paola, United States**

- Moderator: Keith Neeves (United States)  
- Moderator: Jorge Di Paola (United States)

**Thrombus Formation Under Flow: Begins With TF, Can Include Platelet Polyphosphate, and May End With VWF**  
Speaker: Scott Diamond (United States)

**Regulation of VWF Function by ADAMTS13 and Beyond Under Shear**  
Speaker: X. Long Zheng (United States)
Scientific Schedule & Program

Reproducing Thrombosis in ECMO Circuits and Pumps 17:45
Speaker: David Ku (United States)

AVWS and Platelet Abnormalities in Patients With VAD- or ECMO Support 18:15

SSC Session
16:45 - 18:45

Platelet Physiology

Platelet Studies: Methodological Issues, Moderators: Shinji Kunishima, Japan and José Rivera Pozo, Spain
Moderator: Shinji Kunishima (Japan)
Moderator: José Rivera Pozo (Spain)

Study of Platelet Function in Thrombocytopenic Patients: Platelet Adhesion to Collagen in Conditions of Low Platelet Count 16:45
Speaker: Martine Jandrot-Perrus (France)

Study of Platelet Function in Thrombocytopenic Patients: Flow Cytometry 17:05
Speaker: Sofia Ramström (Sweden)

Platelet Physiology: Lessons Learned From Animal Models 17:25
Speaker: Hans Deckmyn (Belgium)

Ageing and Platelet Function 17:45
Speaker: Matthew Rondina (United States)

Platelet-Derived vWF: Methods of Study 18:05
Speaker: Simon De Meyer (Belgium)

Platelets as Vehicles for Drug Delivery 18:25
Speaker: David Wilcox (United States)

SSC Session
16:45 - 18:45

Antigone 1

Hemostasis and Malignancy

Recurrent Venous Thromboembolism and Cancer-Associated Coagulopathy

Neutrophil Extracellular Traps (NETS) in Cancer-Associated Coagulopathy 16:45
Speaker: Johannes Thaler (Austria)

Risk Factors for Recurrent Cancer-Associated Thrombosis 17:15
Speaker: Aurélien Delluc (France)

Tools for Clinical Research and Updates of SSC Initiatives

Statistics for Thrombo-Oncologists 17:45
Speaker: Florian Posch (Austria)
**Scientific Schedule & Program**

**Updates - Coagulopathy in Prostate Cancer Patients Under Androgen Deprivation Therapy**
Speaker: Maha Othman (Canada)  
18:15

**Updates of SSC Initiative and Studies - Incidental PE Registry**
18:25

**Other Updates of SSC Initiative and Studies**
Speaker: Marc Carrier (Canada)  
18:35

---

**SSC Session**
16:45 - 18:45  
Antigone 3

**Plasma Coagulation Inhibitors**

**Working Session 3, Moderator: Cecilia Guillermo, Uruguay**
Moderator: Cecilia Guillermo (Uruguay)  
16:45

**Comparative Schemes for Thrombophilia Testing**
Speaker: Richard Marlar (United States)  
16:45

**Europe- Perspectives #1**
Speaker: Piet Meijer (Netherlands)  
16:50

**Europe- Perspectives #2**
Speaker: Ian Jennings (United Kingdom)  
17:05

**South America**
Speaker: Cecilia Guillermo (Uruguay)  
17:20

**Australia**
Speaker: Emmanuel Favaloro (Australia)  
17:35

**Summary**
Speaker: Richard Marlar (United States)  
17:45

**Working Session 4, Moderator: Hiroko Tsuda, Japan**
Moderator: Hiroko Tsuda (Japan)  
17:55

**Effect of New Anticoagulants on Thrombophilia Assays**
Speaker: Robert Gosselin (United States)  
17:55

**Introduction- Other Functions of the Plasma Coagulation Inhibitors**
Speaker: Richard Marlar (United States)  
18:15

**Protein S Cleavage**
Speaker: Herm Jan Brinkman (Netherlands)  
18:20

**Conclusions & Next Meeting**
Speaker: Richard Marlar (United States)  
18:35
## Predictive and Diagnostic Variables in Thrombotic Disease

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td><strong>Modeling the Risk of Recurrent Venous Thrombosis: Where Are We Now</strong></td>
</tr>
<tr>
<td></td>
<td><strong>and What Can We Add?</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Jasmijn Timp (Netherlands)</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>Individualized Medicine: Prediction of Venous Thrombosis Risk After</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Lower Leg Cast Immobilization and Arthroscopic Knee Surgery</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Banne Nemeth (Netherlands)</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Prediction of Presence of an Occult Malignancy in Patients With a</strong></td>
</tr>
<tr>
<td></td>
<td><strong>First Venous Thrombotic Event</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Soufian Meziyerh (Netherlands)</td>
</tr>
<tr>
<td>17:30</td>
<td><strong>Association Between Risk Factors for Arterial and Venous</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators: Sigrid Braekkan, Norway and John-Bjarne Hansen, Norway</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Sigrid Braekkan (Norway)</td>
</tr>
<tr>
<td></td>
<td>Moderator: John-Bjarne Hansen (Norway)</td>
</tr>
<tr>
<td>17:45</td>
<td><strong>Shared Risk Factors of Arterial and Venous Thrombosis</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Sigrid Braekkan (Norway)</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>What Does the Transient Nature of the Risk Between Arterial and</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Venous Thrombosis Tell Us About Mechanisms Involved?</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Willem Lijfering (Netherlands)</td>
</tr>
<tr>
<td>18:15</td>
<td><strong>Bidirectional Association Between Atrial Fibrillation and Pulmonary</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Embolism</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Erin Hald (Norway)</td>
</tr>
<tr>
<td>19:00</td>
<td><strong>Clinical Implications of the Association Between Arterial and</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Venous Thrombosis</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: John-Bjarne Hansen (Norway)</td>
</tr>
</tbody>
</table>

## Networking Evening

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00</td>
<td><strong>Welcome</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Jean-François Schved (France)</td>
</tr>
<tr>
<td>19:05</td>
<td><strong>Celebrating the 100th Anniversary of the Discovery of Heparin</strong></td>
</tr>
<tr>
<td></td>
<td><strong>The Past, the Present and the Future</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: H.C. Hemker (Netherlands)</td>
</tr>
</tbody>
</table>
Friday, 27. May 2016

Registration
07:00 - 18:30
Level 3

Master Class Session
07:30 - 08:15
Rondelet

Master Class
Simplified Diagnosis of Venous Thrombosis
Speaker: Marc Righini (Switzerland)

Barthez

Master Class
Hemostasis in Liver Failure and/or Liver Regeneration
Speaker: Ton Lisman (Netherlands)

Sully 1

Master Class
Immunological Aspects of Gene Therapy
Speaker: Federico Mingozzi (France)

Sully 2

Master Class
New Insights Into the Contact System
Speaker: Thomas Renne (Sweden)
62nd Annual SSC Meeting of the ISTH,
Montpellier, France,
May 25-28, 2016

Scientific Schedule & Program

Education Session
08:30 - 10:00

Education Session 3 – New Approaches in Therapy: Cell Based Treatments

Co-Chair: Pascale Gaussem (France)
Co-Chair: Jan Astermark (Sweden)

Subclinical Vascular Disease: Evolving Heart and Brain Integration
Speaker: Valentin Fuster (United States)

Cell Based Treatments in Hemophilia
Speaker: David Lillicrap (Canada)

Education Session
08:30 - 10:00

Education Session 4 – Diagnosis and Treatment in Developing Countries: Biology in Developing Countries

Co-Chair: Philippe de Moerloose (Switzerland)
Co-Chair: Emna Gouider (Tunisia)

Quality Control in Developing Countries
Speaker: Steve Kitchen (United Kingdom)

Laboratory Issues in Developing Countries
Speaker: Sukesh Naïr (India)

Diagnosis of Von Willebrand Disease
Speaker: Emmanuel Favaloro (Australia)

Exhibition
09:45 - 17:00

Exhibition

Education Session
10:30 - 12:00

Education Session 3 – New Approaches in Therapy: New Targets

Co-Chair: Anna Randi (United Kingdom)
Co-Chair: Yves Gruel (France)

Factor X Variants in Hemorrhagic Diseases
Speaker: Cecile Denis (France)

Endovascular Therapy for Ischemic Stroke
Speaker: Bruce Campbell (Australia)

Endothelial Progenitors
Speaker: Florence Sabatier (France)
### Education Session 4 – Diagnosis and Treatment in Developing Countries: Treatment of Hemorrhagic Disease in Developing Countries

Co-Chair: Marijke van den Berg (Netherlands)
Co-Chair: Alain Weill (France)

- **10:30**
  - **Lower Doses of Clotting Factor Concentrates: What Can They Achieve?**
    Speaker: Alok Srivastava (India)

- **11:00**
  - **Virus Inactivation of Cryoprecipitate**
    Speaker: Magdy El Ekiaby (Egypt)

- **11:30**
  - **Tranexamic Acid and Non-Substitutive Therapy**
    Speaker: Cedric Hermans (Belgium)

### Corporate Symposium-CS07

**For additional information, please click here**

- **12:45**
  - **Welcome and Introduction**
    Speaker: Augusto Federici (Italy)

- **12:55**
  - **What’s new? rVWF Structure and Functional Specialties**
    Speaker: Peter L. Turecek (Austria)

- **13:20**
  - **VWF Regulation of Angiogenesis and its Clinical Implication**
    Speaker: Anna Randi (United Kingdom)

- **13:50**
  - **Concluding Remarks**
    Speaker: Peter L. Turecek (Austria)

### Corporate Symposium-CS08

**For additional information, please click here**

- **12:45**
  - **Welcome and Introduction**
    Speaker: François Depasse (France)

- **12:50**
  - **Recent Advances in the Diagnosis of Pulmonary Embolism**
    Speaker: Guy Meyer (France)
Scientific Schedule & Program

**Contribution of Thrombin Generation Assay to Patients Management in Clinical Practice**
Speaker: Philip de Groot (Netherlands)

**Coagulation Testing for the DOACs: When and How?**
Speaker: Jeffrey I. Weitz (Canada)

**Concluding Remarks**
Speaker: François Depasse (France)

Corporate Symposium
12:45 - 14:00
Antigone 1

**Corporate Symposium-CS09**
For additional information, please [click here](#)

- **Medscape Education: Beyond Coagulation Factors: New Approaches in the Treatment of Hemophilia A-Medscape Education**
  - **Welcome and Introduction**
    Speaker: Claude Negrier (France)
  - **Unmet Needs in the Treatment of Hemophilia A: Clinician, Patient, and Caregiver Perspectives**
    Speaker: Cedric Hermans (Belgium)
  - **Current and Evolving Therapeutic Options and Management Strategies for Hemophilia A Patients without Inhibitors**
    Speaker: Maria Elisa Mancuso (Italy)
  - **Current and Evolving Therapeutic Options and Management Strategies for Hemophilia A Patients with Inhibitors**
    Speaker: David Lillicrap (Canada)
  - **Novel Approaches for the Management of Hemophilia A With Inhibitors**
    Speaker: Claude Negrier (France)
  - **Concluding Remarks**
    Speaker: Claude Negrier (France)
  - **Questions and Answers**

SSC Session
14:15 - 16:15
Pasteur

**Factor VIII, Factor IX and Rare Coagulation Disorders, Part I**

- **Welcome**
  Speaker: Guy Young (United States)
- **Featured Abstract Presentation: A Novel Factor VIII-Nanobody Fusion Protein Displaying Prolonged Half-Life & Haemostatic Efficacy in Vivo**
  Speaker: Vincent Muczynski (France)
62nd Annual SSC Meeting of the ISTH, Montpellier, France, May 25-28, 2016

**Scientific Schedule & Program**

**SSC Projects, Moderators: Johnny Mahlangu, South Africa and Michael Makris, United Kingdom**
Moderator: Michael Makris (United Kingdom)
Moderator: Johnny Mahlangu (South Africa)

**Inhibitor Reporting Standardization in Previously Treated Patients**
Speaker: Alfonso Iorio (Canada)  14:35

**Bleeding Score in Hemophilia**
Speaker: Maria Elisa Mancuso (Italy)  14:40

**Prophylaxis in Patients Without Inhibitors**
Speaker: Kathelijn Fischer (Netherlands)  14:45

**Standardization of Post-Registration Surveillance**
Speaker: Flora Peyvandi (Italy)  14:50

**Consensus Definitions for Immune Tolerance Induction**
Speaker: Elena Santagostino (Italy)  14:55

**Pharmacokinetics and Population Pharmacokinetics of Factor Concentrates**
Speaker: Alfonso Iorio (Canada)  15:00

**Acquired Hemophilia Definitions**
Speaker: Andreas Tiede (Germany)  15:10

**Gene Therapy, Moderators: Michael Makris, United Kingdom and Elena Santagostino, Italy**
Moderator: Elena Santagostino (Italy)
Moderator: Michael Makris (United Kingdom)

**Definitions of Outcomes: Efficacy and Safety**
Speaker: Alok Srivastava (India)  15:20

**Regulatory Issues With the Approval of Gene Therapy**
Speaker: Annelise Hilger (Germany)  15:35

**Gene Therapy: From Clinical Trials to Clinical Practice**
Speaker: Steve Pipe (United States)  15:40

**Discussion**  16:00

---

**SSC Session**
14:15 - 16:15  Einstein

**Control of Anticoagulation, Part I**

**Introduction**
Speaker: Mark Crowther (Canada)  14:15

**Featured Abstract Presentation: Genetic Dosing Algorithm Underestimates the Warfarin Dose Requirement Among Patients Having Severe Thrombosis or Thrombophilia**
Speaker: Tuukka Helin (Finland)  14:20
62nd Annual SSC Meeting of the ISTH, 
Montpellier, France, 
May 25-28, 2016

Scientific Schedule & Program

Featured Abstract Presentation: VTE Prevention in Acutely Ill Medical Patients With Extended Duration Betrixaban - A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban With Standard of Care Enoxaparin
Speaker: Alexander Thomas Cohen (United Kingdom)
Speaker: C. Michael Gibson (United States)

Laboratory Testing of the New Anticoagulants: Where Are We in 2016? , Moderator: Ismail Elalamy, France
Moderator: Ismail Elalamy (France)

Role of Traditional Laboratory Tests in Evaluating Critically Ill Patients: A Focus on Direct Oral Anticoagulants
Speaker: Adam Cuker (United States)

Overview of Standardization Efforts for Laboratory Assays
Speaker: Steve Kitchen (United Kingdom)

Specific Tests for Xa Inhibitors
Speaker: Isabelle Gouin-Thibault (France)

Specific Tests for IIa Inhibitors
Speaker: Jonathan Douxfils (Belgium)

Point of Care Assays
Speaker: Edelgard Lindhoff-Last (Germany)

SSC Session
14:15 - 16:15
Antigone 1

Animal, Cellular and Molecular Models of Thrombosis

Session 1, Moderator: Tom Knudsen, Denmark
Moderator: Tom Knudsen (Denmark)

Featured Abstract Presentation: Platelets Promote MMP-Dependent Plaque Deposition Locally at the Site of Vascular Injury
Speaker: Tom Mastenbroek (Netherlands)

SSC Project - Design & Objectives: Comparative Evaluation of Murine Bleeding Models
Speaker: Tom Knudsen (Denmark)

In Vivo Imaging of Thrombosis and Hemostasis
Speaker: Timothy Stalker (United States)

Cellular and Animal Models of Immunogenicity, Moderator: Denise Sabatino, United States
Moderator: Denise Sabatino (United States)

Cellular Models of Immunogenicity
Speaker: Sebastien Lacroix-Desmazes (France)

Humanized Animal Models for Preclinical Immunogenicity Assessment of Protein Therapeutics - Opportunities and Limitations
Speaker: Birgit Reipert (Austria)
Scientific Schedule & Program

Characterization of the Immune Response to FVIII in F8-KO Rats 15:45
Speaker: Karin Lövgren (Denmark)

SSC Business Meeting - Including Discussion of Topics for 2017 Meeting,
Moderator: Tom Knudsen, Denmark

Topics for Next Year’s Meeting 16:05
Speaker: Tom Knudsen (Denmark)

SSC Session
14:15 - 16:15
Antigone 3

Vascular Biology

Introduction 14:15
Speaker: Rienk Nieuwland (Netherlands)

Featured Abstract Presentation: Activated Protein C (APC) Down
Regulates Neutrophil Extracellular Traps (NETs): Potential Contributing
Mechanism for Anti-Inflammatory and Antithrombotic Effects of APC 14:20
Speaker: Laura D Healy (United States)

Extracellular Vesicles, Moderators: Chris Gardiner, United Kingdom and
Pia Siljander, Finland
Moderator: Pia Siljander (Finland)
Moderator: Chris Gardiner (United Kingdom)

Role of EV-Bound Polyphosphate-Factor XII in Prostate Cancer-Driven
Thrombosis 14:35
Speaker: Katrin Nickel (Sweden)

TF-EV in Clinical Trials and the Need for Standardization 14:55
Speaker: Johannes Thaler (Austria)

Desirable Properties of TF-EV Reference Preparation 15:15
Speaker: Chris Gardiner (United Kingdom)

Consideration and Challenges in Generating Reference Materials 15:35
Speaker: Elaine Gray (United Kingdom)

Endothelial Progenitor Cells, Moderators: Anna Randi, United Kingdom
and Florence Sabatier, France
Moderator: Anna Randi (United Kingdom)

The BOEC as a Model for Organ-Specific Endothelial Assessment - Apples
Versus Oranges? 15:55
Speaker: Mark Toshner (United Kingdom)

Genomics in Thrombosis and Hemostasis
Featured Abstract Presentation: Design and Application of a Twenty-Three-Gene Panel by Next-Generation Sequencing for Inherited Coagulation Bleeding Disorders
Speaker: Jose Maria Bastida (Spain)

Session 1, Moderator: Willem Ouwehand, United Kingdom
Moderator: Willem Ouwehand (United Kingdom)

ThromboGenomics High Throughput Sequencing Platform
Speaker: Kate Downes (United Kingdom)

Statistical Challenges of Identifying the Genetic Determinants of Rare Diseases
Speaker: Ernest Turro (United Kingdom)

Session 2, Moderator: Andreas Greinacher, Germany
Moderator: Andreas Greinacher (Germany)

Assigning Pathogenicity Status to DNA Variants
Speaker: Kathleen Freson (Belgium)

Reference Variant Databases
Speaker: Karen Megy (United Kingdom)
Speaker: Muriel Giansily-Blaizot (France)

SSC Session
14:15 - 16:15
Barthez

Factor XI and the Contact System

Featured Abstract Presentation: Assessment of Small Molecular Weight Inhibitors of the Contact Pathway
Speaker: Charlotte Bouckaert (Belgium)

Interaction of the Contact System With Pathogens
Speaker: Heiko Herwald (Sweden)

Factor XI Improves Host Defense During Pneumonia-Derived Sepsis Independent of Factor XII Activation
Speaker: Ingrid Stroo (Netherlands)

New Tools to Study Contact Activation
Speaker: Steffen Rosén (Sweden)

Functional and Antigenic Value Assignments for the 2nd International Standard for Blood Coagulation Factor XI, Plasma
Speaker: Helen Wilmot (United Kingdom)

Consideration on the Feasibility of Establishing an International Standard for FXII
Speaker: Helen Wilmot (United Kingdom)

Nomenclature Proposal for the Contact System
Speaker: Alvin Schmaier (United States)
Factor VIII, Factor IX and Rare Coagulation Disorders, Part I

The SIPPET Study: Results, Analysis and Debate, Moderators: Gili Kenet, Israel and Johnny Mahlangu, South Africa
Moderator: Johnny Mahlangu (South Africa)
Moderator: Gili Kenet (Israel)

Results of the SIPPET Study
Speaker: Flora Peyvandi (Italy)

Debate: Plasma-Derived FVIII Concentrates for PUPs: Yes or No
Speaker: Manuel Carcao (Canada)
Speaker: Kathelijn Fischer (Netherlands)

SIPPET Study Stakeholders Discussion
Speaker: Brian O'Mahony (Ireland)
Speaker: Marijke van den Berg (Netherlands)
Speaker: Stephanie Seremetis (United States)
Speaker: Garrett Bergman (United States)

Control of Anticoagulation, Part I

Update on Current and Proposed Registries, Standardization Activities and Membership Surveys, Moderator: Benilde Cosmi, Italy
Moderator: Benilde Cosmi (Italy)

Moving the Committee Forward: Next Steps
Speaker: Mark Crowther (Canada)

Restarting Anticoagulation After Intracerebral Hemorrhage
Speaker: Yan Xu (Canada)

Registry of CVT
Speaker: Francesco Dentali (Italy)

Replacement of the Current International Standards for Thromboplastin

Lupus Anticoagulant Testing in Anticoagulated Patients
Speaker: Armando Tripodi (Italy)

New Proposals - Open Session
Speaker: Mark Crowther (Canada)
Speaker: Francesco Dentali (Italy)

Vascular Biology
Scientific Schedule & Program

Standardization of Measurements of Extracellular Vesicles (EV),
Moderators: Rienk Nieuwland, The Netherlands
Moderator: Rienk Nieuwland (Netherlands)

Standardization of Microparticle Enumeration Across Different Flow
Cytometry Platforms: Results of a Multicentre Collaborative Workshop
and Future Directions
Speaker: Romaric Lacroix (France)

Quantitative Light Scattering to Standardize Flow Cytometry
Measurements of Extracellular Vesicles
Speaker: Edwin van der Pol (Netherlands)

Size and Refractive Index Determination by Flow Cytometry Discriminate
Extracellular Vesicles From Lipoprotein Particles
Speaker: Leonie de Rond (Netherlands)

Shedded Proteins and Receptors, Moderators: Elizabeth Gardiner,
Australia
Moderator: Elizabeth Gardiner (Australia)

Soluble Glycoprotein VI in Thermal Injury
Speaker: Paul Harrison (United Kingdom)

Platelet Receptors and Coagulopathy
Speaker: Robert Andrews (Australia)

SSC Session
16:45 - 18:45

Genomics in Thrombosis and Hemostasis

Session 3, Moderator: Paolo Gresele, Italy
Moderator: Paolo Gresele (Italy)

Regulation of Haemostasis by miRNAs: Implications for Thrombus
Formation
Speaker: Martinez Gomez (Spain)

Differential Diagnosis of Congenital Macrothrombocytopenia
Speaker: Shinji Kunishima (Japan)

Reprogramming of Platelet Mirnome Induced by Activation
Speaker: Giovanni Cimmino (Italy)

Session 4, Moderator: Kathleen Freson, Belgium
Moderator: Kathleen Freson (Belgium)

Common Gene Variations Affecting Platelet Function
Speaker: Leonard Edelstein (United States)

Phenotyping and Genotyping Inherited Platelet Disorders: Experience
From a Spanish National Project
Speaker: José Rivera Pozo (Spain)
### Scientific Schedule & Program

**Panel Discussion: Sharing Genotype and Phenotype Data in Inherited Disorders** 18:25

**SSC Session**

**16:45 - 18:45**

**Factor XI and the Contact System**

**Zinc Binding to Factor XII**
Speaker: Bubacarr Kaira (United Kingdom) 16:45

**Contact System in Hemostasis**
Speaker: Edward Feener (United States) 17:00

**Update on the Clinical Development of Factor XI Inhibitors**
Speaker: Jeffrey I. Weitz (Canada) 17:15

**Polyphosphates and the Contact System**
Speaker: Stephanie Smith (United States) 17:30

**Polyphosphate Crystals on the Platelet Surface**
Speaker: Coen Maas (Netherlands) 17:45

**Contact System and Leukocyte Function**
Speaker: Evi Stavrou (United States) 18:00

**Prekallikrein and Bradykinin B2 Receptor Modulate Thrombosis Risk Through Renin-Angiotensin System and Vessel Wall Tissue Factor**
Speaker: Alvin Schmaier (United States) 18:15

**Factor XI and the Contact System in Thrombosis**
Speaker: Erik Tucker (United States) 18:30

**Closure**
Speaker: Joost Meijers (Netherlands) 18:44

**Corporate Symposium**

**19:00 - 20:00**

**Corporate Symposium-CS10**

For additional information, please [click here](#)

**AKH Inc.: New Treatment Strategies for Extended VTE Prophylaxis**

**Risk of VTE Events in Acutely Medically Ill Patients and in the Post-Acute Setting: What are the Current Standards of Care?**
Speaker: Alexander Thomas Cohen (United Kingdom) 19:00

**Evidence for Use of D-Dimer, Age, and Other Risk Factors for Determining Extended VTE Prophylaxis in Medically Ill Patients**
Speaker: Jeffrey I. Weitz (Canada) 19:10
### Scientific Schedule & Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:20</td>
<td>Emerging Factor Xa Inhibitors for Extended VTE Prophylaxis for Assisting With the Transitions of Care</td>
<td>Alexander Thomas Cohen (United Kingdom)</td>
</tr>
<tr>
<td>19:40</td>
<td>Extended VTE Prophylaxis Therapy: Improving Patient Clinical Outcomes, Reducing Healthcare Readmissions, and Decreasing Costs</td>
<td>Jeffrey I. Weitz (Canada)</td>
</tr>
<tr>
<td>19:50</td>
<td>Faculty Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 28. May 2016

Registration
07:30 - 13:00
Level 3

Registration

SSC Session
08:30 - 10:30
Pasteur

Factor VIII, Factor IX and Rare Coagulation Disorders, Part II

Rare Bleeding Disorders, Moderators: Manuel Carcao, Canada and Danijela Mikovic, Serbia
Moderator: Manuel Carcao (Canada)
Moderator: Danijela Mikovic (Serbia)

Factor XIII Prospective Study: Update and Current Initiatives
Speaker: Flora Peyvandi (Italy) 08:30

Next Generation Testing for Rare Bleeding Disorders
Speaker: Diane Nugent (United States) 08:40

Plasminogen Deficiency: Current Trials and Future Initiatives
Speaker: Amy Shapiro (United States) 08:50

Discussion
09:00

Extended Half-Life Products: Clinical Issues and Debate, Moderators: Manuel Carcao, Canada and Guy Young, United States
Moderator: Manuel Carcao (Canada)
Moderator: Guy Young (United States)

Measuring the Extended Half-Life Products—Where Is the Problem?
Speaker: Steve Kitchen (United Kingdom) 09:15

Debate on the Use of Extended Half-Life FVIII: Is It Worth Switching?
Speaker: Amy Dunn (United States) 09:30

Debate on the Use of Extended Half-Life FIX: Should All Patients Be Switched?
Speaker: Johnny Mahlangu (South Africa) 09:55

Discussion
10:20

SSC Session
08:30 - 10:30
Einstein

Control of Anticoagulation, Part II

Introduction
Speaker: Mark Crowther (Canada) 08:30
### Managing Bleeding With DOACS: Current State of the Art, Moderator: Walter Ageno, Italy
Moderator: Walter Ageno (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:35</td>
<td>Real World Bleeding Rates With DOACS</td>
<td>Jan Beyer-Westendorf</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Germany)</td>
</tr>
<tr>
<td>09:00</td>
<td>Non-Specific Reversal Strategies</td>
<td>Peter Verhamme</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Belgium)</td>
</tr>
<tr>
<td>09:30</td>
<td>Xa Inhibitors: Specific Reversal Agents and Use</td>
<td>Mark Crowther</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Canada)</td>
</tr>
<tr>
<td>10:00</td>
<td>IIa Inhibitors: Specific Reversal Agents and Use</td>
<td>Peter Verhamme</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Belgium)</td>
</tr>
</tbody>
</table>

### SSC Session
08:30 - 10:30

#### Antigone 1

### Platelet Immunology

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Introduction and Welcome</td>
<td>Donald Arnold (Canada)</td>
</tr>
<tr>
<td></td>
<td>Featured Abstract Presentation: Platelet Proteomics Profiling in Transfusion Adverse Events</td>
<td>Chaker Aloui (France)</td>
</tr>
<tr>
<td>08:40</td>
<td>Immunoassays for Investigation of ITP and Use of Appropriate Controls</td>
<td>Donald Arnold (Canada)</td>
</tr>
<tr>
<td>08:55</td>
<td>The Importance of Lectins in ITP: Effect of Anti-PLT Antibodies, Use of Lectins to Detect Carbohydrate Residues on PLTs</td>
<td>Tamam Bakchoul (Germany)</td>
</tr>
<tr>
<td>09:25</td>
<td>Evaluation of The &quot;&quot;Eva&quot;&quot; Assay: A New Diagnostic Tool in Platelet Immunology</td>
<td>Véronique Denays (Belgium)</td>
</tr>
<tr>
<td>09:40</td>
<td>Discussion and Work Plan</td>
<td>Tamam Bakchoul (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shigeki Miyata (Japan)</td>
</tr>
<tr>
<td>09:55</td>
<td>Standard Approach to NAIT Laboratory Investigations</td>
<td>Donald Arnold (Canada)</td>
</tr>
<tr>
<td>10:10</td>
<td>Integrins Polymorphisms: Molecular Dynamics and Allostery</td>
<td>Vincent Jallu (France)</td>
</tr>
</tbody>
</table>
Scientific Schedule & Program

Discussion and Work Plan
Speaker: Donald Arnold (Canada) 10:25

SSC Session
08:30 - 10:30 Antigone 3

Women’s Health Issues in Thrombosis and Hemostasis

Welcome and Introduction of Subcommittee Co-Chairs 08:30
Speaker: Rezan Kadir (United Kingdom)

Speaker: Leslie Skeith (Canada)

Report on the WHITH Meeting 08:50
Speaker: Benjamin Brenner (Israel)

Educational Activities - Update on International Registries and SSC Initiated Projects, Moderators: Hannah Cohen, United Kingdom and Ida Martinelli, Italy
Moderator: Hannah Cohen (United Kingdom)
Moderator: Ida Martinelli (Italy)

DOAC and Pregnancy: Registry 09:00
Speaker: Saskia Middeldorp (Netherlands)

The Use of Thrombo-Elastography in Pregnancy: Registry 09:05
Speaker: Maha Othman (Canada)

Assessment of the Thrombogenic Potential of Ovarian Stimulation / in Vitro Fertilization 09:10
Speaker: Angela Pereira (United Kingdom)

PBAC Score: A Tool for Prediction of Coagulation Disorders in Women With Heavy Menstrual Bleeding 09:15
Speaker: Susan Halimeh (Germany)

Risks of Thromboembolism Associated With Hormonal Contraceptives in Japanese Women 09:20
Speaker: Takao Kobayashi (Japan)

Artemis Study 09:30
Speaker: Menno Huisman (Netherlands)

Discussion 09:40

Thrombosis - Session, Moderators: Ian Greer, United Kingdom and Maha Othman, Canada
Moderator: Maha Othman (Canada)
Moderator: Ian Greer (United Kingdom)

Management of Pregnancy Complications: Precision Medicine Approach 09:50
Speaker: Ian Greer (United Kingdom)
Thrombosis, Cancer and Women’s Health: Lessons From RIETE
Speaker: Manuel Monreal (Spain)

Factor XIII and Fibrinogen

Cellular Factor XIII: A Fascinating Story
Speaker: Laszlo Muszbek (Hungary)

Standardisation of Turbidity and Fibrinolysis Measurements
Speaker: Marlien Pieters (South Africa)

FXIII-B Standardisation Update
Speaker: Laszlo Muszbek (Hungary)
Speaker: Eva Katona (Hungary)

Do We Need Novel Guidelines for Diagnosis, Classification and Management of FXIII Deficiency?
Speaker: Verena Schroeder (Switzerland)

Biorheology

Introductory Remarks
Speaker: Keith Neeves (United States)

Featured Abstract Presentation: Outward Migration of Procoagulant Platelets to Thrombus Surface is Driven by Thrombus Contraction and Decreased Adhesivity
Speaker: Dmitry Nechipurenko (Russian Federation)

Synthetic Platelets and Engineered Microparticles for Hemostasis and Drug Delivery, Moderator: Warwick Nesbitt, Australia
Moderator: Warwick Nesbitt (Australia)

Platelet-Inspired Biomedical Technologies: From Synthetic Hemostats to Targeted Drug Delivery Systems
Speaker: Anirban Sen Gupta (United States)

Synthetic and Genetically Engineered Platelets for Therapeutic Targeting of Circulating Tumor Cells
Speaker: Michael King (United States)

Magnetically Propelled Microwheels for Rapid Thrombolysis
Speaker: Keith Neeves (United States)

Discussion on Translational Challenges With Synthetic Platelets
Factor VIII, Factor IX and Rare Coagulation Disorders, Part II

What's New in Inhibitor Management?, Moderators: Gili Kenet, Israel and Guy Young, United States
Moderator: Guy Young (United States)
Moderator: Gili Kenet (Israel)
Framing the Inhibitor Problem
Speaker: Donna DiMichele (United States)
Collaborative Study to Assess Inter-Laboratory Variability Using SMIA and Nijmegen Inhibitor
Speaker: Sanj Raut (United Kingdom)
Alternative Approaches Using Current Therapies
Speaker: Gili Kenet (Israel)
Future Therapies for Inhibitor Patients
Speaker: David Lillicrap (Canada)
Inhibitor Management in 2020: Perspectives From the SSC Subcommittee and Open Discussion
Speaker: Guy Young (United States)

Control of Anticoagulation, Part II

State of the Art Lecture, Moderator: Elanie Hylek, United States
Moderator: Elanie Hylek (United States)
Special State of the Art Lecture: Where Will Anticoagulant Therapy Be in 5 Years?
Speaker: Jeffrey I. Weitz (Canada)
Guidelines in Antithrombotic Therapy: Where Are We and What Is Coming?, Moderator: Elaine Hylek, United States
Moderator: Elaine Hylek (United States)
ASH VTE Guidelines: Current State and Publication/Dissemination Plans
Speaker: Saskia Middeldorp (Netherlands)
ISTH Guideline Process and Current and Proposed Topics
Speaker: Alberto Tosetto (Italy)
ACCP Guidelines: Current and Future State
Speaker: Clive Kearon (Canada)
ESC Guidelines: Current State and Plans for Updating
Speaker: Stavros Konstantinides (Germany)
AC Forum Guidance Documents: Impact and Future Plans
Speaker: Mark Crowther (Canada)
Open Session: Additional Guideline Initiatives  
Speaker: Mark Crowther (Canada)  

Platelet Immunology

Heparin Induced Thrombocytopenia, Moderators: Francois Mullier, Belgium and Chris Ward, Australia  
Moderator: Chris Ward (Australia)  
Moderator: Francois Mullier (Belgium)

Diagnostic Value of Immunoassays for Heparin-Induced Thrombocytopenia  
Speaker: Michael Nagler (Switzerland)

Multiplate Assay for HIT Diagnosis: Survey Results and Standardized Protocol  
Speaker: Chris Ward (Australia)

Exogenous PF4 to Differentiate Pathogenic and Non-Pathogenic Antibodies  
Speaker: Ishac Nazi (Canada)

Beneficial Effect of Exogenous PF4 on SRA for Detecting Pathogenic HIT Antibodies  
Speaker: Claire Pouplard (France)

A Flow-Based Washed Platelet Assay for HIT  
Speaker: Shigeki Miyata (Japan)

HIT Antibodies With Heparin-Independent Platelet-Activation: Clinical Implications  
Speaker: Theodore Warkentin (Canada)

Discussion and Work Plan  
Speaker: Chris Ward (Australia)  
Speaker: Francois Mullier (Belgium)

Final Wrap-Up  
Speaker: Donald Arnold (Canada)

Women’s Health Issues in Thrombosis and Hemostasis

Thrombosis - Session Continued, Moderators: Ian Greer, United Kingdom and Maha Othman, Canada  
Moderator: Maha Othman (Canada)  
Moderator: Ian Greer (United Kingdom)
**Scientific Schedule & Program**

**Antenatal and Peri-Delivery Anticoagulant Management**  
Speaker: Hannah Cohen (United Kingdom)  
11:00

**Hypatia**  
Speaker: Karen Schreiber (United Kingdom)  
11:20

**Hemostasis Session, Moderators: Rezan Kadir, United Kingdom and Rochelle Winikoff, Canada**  
Moderator: Rezan Kadir (United Kingdom)  
Moderator: Rochelle Winikoff (Canada)

**Obstetric DIC**  
Speaker: Offer Erez (Israel)  
11:40

**VWD and Pregnancy**  
Speaker: Nathalie Itzhar Baikian (France)  
12:00

**FXIII Deficiency in Women**  
Speaker: Laszlo Muszbek (Hungary)  
12:20

**FXI Deficiency and Pregnancy**  
Speaker: Bethan Myers (United Kingdom)  
12:40

**Conclusions and Meeting Closure**  
Speaker: Rezan Kadir (United Kingdom)

---

**Rondelet**

**Factor XIII and Fibrinogen**

**Featured Abstract Presentation: Visual Quantification of Fibrin Network Density**  
Speaker: Joke Konings (Netherlands)  
11:00

**Strategies for Characterizing the Reactivity of Factor XIII Toward Fibrinogen**  
Speaker: Muriel Maurer (United States)  
11:20

**New and Replacement WHO Reference Materials for Ancrod and Batroxobin**  
Speaker: Craig Thelwell (United Kingdom)  
11:45

**Pro-RBDD Study: New Insights on the Minimal Residual FXIII Coagulant Activity to Prevent Spontaneous Major Bleeding**  
Speaker: Marzia Menegatti (Italy)  
12:10

**Discussion**  
12:35

---

**Barthez**

**Biorheology**
Scientific Schedule & Program

Novel Methods and Concepts in Thrombus Formation Under Flow,
Moderator: Erik Westein, Australia
Moderator: Erik Westein (Australia)

Regulation of Arterial Thrombus Size and Structure: Biochemistry Versus (Hydro) Mechanics
Speaker: Mikhail Panteleev (Russian Federation) 11:00

Different Types of Procoagulant Platelets in a Thrombus: Just a Matter of Definitions?
Speaker: Judith Cosemans (Netherlands) 11:25

Application of a Shear Microgradient Microfluidic Assay for Von Willebrand’s Disease Screening
Speaker: Warwick Nesbittt (Australia) 11:50

Disturbed Blood Flow Promotes Efficient Thrombus Growth on Weak Adhesive Surfaces
Speaker: Pierre Mangin (France) 12:15

Microfluidic Platform for Automated Endothelial Cell Culture Enabling Real Time Visualization of Blood Cell Function Under Flow
Speaker: Crispin Szydzik (Australia) 12:40